

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Omega-3 polyunsaturated fatty acid supplementation for improving peripheral nerve health: protocol for a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020804
Article Type:	Protocol
Date Submitted by the Author:	24-Nov-2017
Complete List of Authors:	Zhang, Alexis; The University of Melbourne, Department of Optometry and Vision Sciences MacIsaac, Richard J.; St Vincent's Hospital Melbourne, Department of Endocrinology and Diabetes; The University of Melbourne, Department of Medicine Roberts, Leslie; The University of Melbourne, Department of Medicine; St Vincent's Hospital Melbourne, Centre for Clinical Neurosciences and Neurological Research Kamel, Jordan; The University of Melbourne, Department of Medicine; St Vincent's Hospital Melbourne, Centre for Clinical Neurosciences and Neurological Research Craig, Jennifer; University of Auckland, Department of Ophthalmology Busija, Lucy ; Australian Catholic University,, Institute for Health and Ageing Downie, Laura; The University of Melbourne, Department of Optometry and Vision Sciences
Keywords:	Diabetic neuropathy < DIABETES & ENDOCRINOLOGY, NEUROLOGY, Adult neurology < NEUROLOGY, Neuropathology < NEUROLOGY, THERAPEUTICS

SCHOLARONE™
Manuscripts

Omega-3 polyunsaturated fatty acid supplementation for improving peripheral nerve health: protocol for a systematic review

Alexis Ceecee Zhang,¹ Richard MacIsaac,^{2,3} Leslie Roberts,^{3,4} Jordan Kamel,^{3,4}

Jennifer Craig,⁵ Lucy Busija,⁶ Laura Elizabeth Downie¹

¹Department of Optometry and Vision Sciences, The University of Melbourne, Parkville, Victoria, Australia 3010; ²Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia 3065; ³Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia 3010; ⁴Centre for Clinical Neurosciences and Neurological Research, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia 3065; ⁵Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand 1023; ⁶Institute for Health and Ageing, Australian Catholic University, Fitzroy, Victoria, Australia 3065.

Word count: 4175 words

Corresponding author:

Dr Laura Downie

Department of Optometry and Vision Sciences

Level 4, Alice Hoy Building (Building 162)

The University of Melbourne, Parkville Victoria Australia 3010

Ph: +61 3 9035 3043, Fax: +61 3 9035 9905

Email: ldownie@unimelb.edu.au

ABSTRACT

Introduction: Damage to peripheral nerves occurs in a variety of health conditions. Preserving nerve integrity, to prevent progressive nerve damage, remains a clinical challenge. Omega-3 polyunsaturated fatty acids (PUFAs) are implicated in the development and maintenance of healthy nerves and may be beneficial for promoting peripheral nerve health. The aim of this systematic review is to assess the effects of oral omega-3 PUFA supplementation on peripheral nerve integrity, including both subjective and objective measures of peripheral nerve structure and/or function.

Methods and analysis: A systematic review of randomised controlled trials that have evaluated the effects of omega-3 PUFA supplementation on peripheral nerve assessments will be conducted. Comprehensive electronic database searches will be performed in OVID Medline, Embase, the Cochrane Central Register of controlled Trials (CENTRAL), US National Institutes of Health Clinical Trials Registry and the World Health Organisation International Clinical Trials Registry Platform (WHO ICTRP). The title, abstract and keywords of identified articles will be assessed for eligibility by two reviewers. Full text articles will be obtained for all studies judged as eligible or potentially eligible; these studies will be independently assessed by two reviewers to determine eligibility. Disagreements will be resolved by consensus. Risk of bias assessment will be performed using the Cochrane Collaboration risk of bias tool to appraise the quality of included studies. If clinically meaningful, and there are a sufficient number of eligible studies, a meta-analysis will be conducted and a summary of findings table will be provided.

Ethics and dissemination: This is a systematic review that will involve the analysis of previously published data and therefore ethics approval is not required. A

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

manuscript reporting the results of this systematic review will be published in a peer-reviewed journal and may also be presented at relevant scientific conferences.

For peer review only

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This will be the first systematic review to consider the efficacy and safety of omega-3 PUFA supplementation on peripheral nerve structure and function.
- This systematic review will only consider data from randomised controlled trials, which provide the highest level of evidence for single intervention studies.
- This review will be conducted according to the Cochrane Handbook for Systematic Reviews of Interventions, and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) statement.
- As we will include studies that have evaluated the use of omega-3 PUFA supplementation for treating any form of peripheral nerve damage, there may be limited scope to perform a meta-analysis due to clinical heterogeneity.
- There are currently no gold standard outcome measures for assessing peripheral neuropathy, which may affect the capacity to quantitatively synthesise data from individual studies to derive clear estimates of treatment effect(s).

BACKGROUND

Description of the condition

The peripheral nervous system encompasses the nerves mediating sensory, motor and autonomic functions that are located outside of the brain and spinal cord. Alterations to the anatomical integrity of the peripheral nerves can adversely affect their function, presenting clinically as abnormal or loss of sensation, weakness and/or as changes to autonomic function.[1] England describes peripheral neuropathy as “a general term that indicates any disorder of the peripheral nervous system;”[2] this is a broad definition that includes nerve damage due to a variety of aetiologies. The pathophysiological mechanisms underlying both the development and progression of peripheral neuropathy are complex and may depend on the cause. Mechanisms may involve altered metabolism and intracellular signaling,[3] vascular and inflammatory stress,[4] and reactive oxygen species formation.[5]

The most common systemic cause of peripheral neuropathy, which is evident in over 50% of individuals affected by the condition, is diabetes mellitus; the risk of peripheral neuropathy increases with longer disease duration,[6] and is correlated with the degree of glycaemic control.[7] Other causes include hereditary neuropathies (e.g., Charcot-Marie-Tooth Syndrome), post-infectious and inflammatory neuropathies (e.g., Guillain-Barré Syndrome) and drug-induced neuropathies (e.g. platinum analogues, thalidomide, alcohol).[8] Up to one-third of cases do not have an identified aetiology, and are thus defined as idiopathic peripheral neuropathies.[9]

Clinical evaluations of peripheral nerve integrity generally include a combination of symptoms, signs and electrodiagnostic studies, which aim to evaluate the extent of

1
2
3 nerve damage.[2] Symptoms and signs of nerve damage are often assessed using
4 validated neuropathy scales or composite scores (which combine symptomatology
5 with clinical measures of nerve function). Nerve biopsies are invasive and, as a result,
6 not easily repeatable, and are therefore not frequently used as an outcome parameter
7 in longitudinal studies, but are rather reserved for diagnostic purposes.[10]
8
9
10
11
12

13
14
15
16 Electrodiagnostic testing examines the characteristics of the conduction of an
17 electrical signal that travels through a single nerve. These tests are useful in providing
18 diagnostic information and for longitudinally monitoring disease progression.[11]
19 Nerve conduction studies are reproducible and correlate well with underlying
20 structural abnormalities,[12] but the precision of these tests is limited to detecting
21 changes in large myelinated nerve fibres, as they are not sufficiently sensitive to
22 detect small nerve fibre damage.[13, 14] Quantitative sensory tests, which quantify
23 thermal and pain thresholds, can be used to evaluate small nerve fibre function.[14]
24
25 Skin biopsies offer an alternative method to accurately diagnose and classify the
26 extent of small fibre neuropathy, even in the absence of large fibre nerve damage.[14,
27 15] Cutaneous silent period (CSP) testing is a reproducible measurement of the
28 nonceptive spinal reflex where thinly myelinated A-delta fibres are the afferent arm.
29 Quantitative sudomotor axonal reflex testing (QSART) assesses the function of
30 unmyelinated post-ganglionic sudomotor C-fibres.[16, 17] These are amongst several
31 other methods to assess various small fibre types, and as each individual test may
32 have a relatively low sensitivity a combination of modalities is usually preferable to
33 better assess small fibre function.[18]
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Recently, corneal confocal microscopy has been applied to visualise small nerve
4 fibres *in vivo*.^[19] This technique has been shown to correlate well with
5 intraepidermal nerve fibre biopsy results^[20] and is useful for detecting and
6 documenting various types of small fibre neuropathies.^[21-24] Corneal confocal
7 microscopy has also been suggested to be useful for monitoring disease progression,
8 and as a marker for improvements in nerve function, in the investigation of
9 therapeutic targets for diabetic peripheral neuropathy.^[25-27]

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Peripheral neuropathies are typically treated based on their subtype and/or underlying
cause(s). Treatments primarily aim to manage the underlying condition to prevent
progressive nerve damage and to treat any associated symptoms.^[2, 13, 28] The
consequences associated with symptoms of neuropathic impairment do not only affect
an individual's quality of life, but remain an economic burden in the cost of
healthcare and medical resources.^[29-31] This is especially true in chronic conditions
such as diabetes, where lifetime care is required.^[3]

Description of the intervention

40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Omega-3 polyunsaturated fatty acids (PUFAs) are essential fatty acids (EFAs) with
multiple double bonds, the first of which is located at the third carbon from the
methyl end of the molecule. Short-chain omega-3 PUFAs, alpha-linolenic acid
(ALA), found in plant sources, is a metabolic precursor to the long-chain omega-3
PUFAs docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are
present in high abundance in oily fish. As humans do not have the enzymes to
synthesise these fatty acids *de novo*, omega-3 PUFAs must be obtained from the diet
or through supplementation.^[32] The other major class of EFAs are the omega-6 fatty

1
2
3 acids, which derive from the diet in the form of linolenic acid (LA) and are elongated
4 *in vivo* to gamma-linoleic acid (GLC) and arachidonic acid (AA). Most eicosanoids
5 derived from the omega-6 dependent AA-pathway are pro-inflammatory; in contrast,
6 long-chain omega-3 fatty acids bias prostaglandin metabolism towards the production
7 of anti-inflammatory eicosanoids.
8
9
10
11
12

13
14
15 As omega-3 PUFAs competitively inhibit the metabolic conversion of omega-6
16 PUFAs,[33] the balance of omega-3 to omega-6 fatty acid consumption can affect
17 systemic inflammatory processes and immune activity. The ratio of consumed omega-
18 6 to omega-3 in typical Western diets is approximately 15 to 1, whereas a ratio of 4 to
19 1 is considered optimal.[34] Increased consumption of omega-3 PUFAs is considered
20 to provide a range of potential general health benefits, including a reduced risk of
21 cardiovascular disease[35, 36] and lowered systemic triglycerides[37]. DHA, as an
22 integral component in cellular membrane structures of the brain and retina, has been
23 implicated in perinatal visual and neural development.[38-40] In ocular conditions,
24 omega-3 fatty acids supplements can reduce the symptoms and clinical signs
25 associated with ocular surface inflammation in dry eye disease.[41] The American
26 Heart Foundation recommends a daily intake, for adults, of 500mg of long-chain
27 omega-3 PUFAs,[42] and up to 4g/day in hypertriglyceridemia.[43]
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **How the intervention might work**

47
48 Once consumed, omega-3 PUFAs alter membrane protein activity and cellular
49 signaling response, to reduce immune activity and the concentration of systemic lipid
50 inflammatory mediators.[44] The incorporation of omega-3 PUFAs into cellular
51 membranes, and their subsequent effect on membrane activity, has been shown to
52
53
54
55
56
57
58
59
60

1
2
3 alter vascular function, improve sciatic nerve blood flow and enhance nerve
4
5 conduction velocity in a rat model of experimental diabetic neuropathy.[45]
6
7

8
9
10 Omega-3 PUFAs also affect intracellular signalling pathways and the expression of
11
12 genes, some of which may be associated with the regulation of neuron growth and
13
14 neuroprotection.[46] In animal models of diabetes, omega-3 PUFA supplementation
15
16 has been shown to attenuate adverse changes in nerve structure and function.[47, 48]
17
18 Mice enriched with genes that increase endogenous profiles of omega-3 PUFAs have
19
20 been shown to have reduced neuronal cell death and increased recovery to mechanical
21
22 stress and peripheral nerve injury.[49] Omega-3 PUFAs have also been demonstrated
23
24 to promote neurite growth in rat sensory neurons.[50]
25
26

27
28
29 Derivatives of omega-3 PUFA metabolism, resolvins and protectins, which are
30
31 oxygenated metabolites from EPA and DHA respectively, may further promote
32
33 neuronal function. Neuroprotectin D-1 has been shown to facilitate the regeneration
34
35 of corneal nerves following refractive surgery and neurite growth from the trigeminal
36
37 ganglion of mice [51] and to prevent neuropathic pain after peripheral nerve
38
39 injury.[52]
40
41

42 43 44 **Why it is important to do this review**

45
46 This will be the first systematic review to consider the potential effects of omega-3
47
48 PUFA supplementation on peripheral nerve integrity. Omega-3 PUFA
49
50 supplementation has been shown to reduce neuronal damage and enhance recovery
51
52 following nerve injury in experimental animal models of peripheral neuropathy.
53
54 Confirmation of these effects in clinical populations would contribute significantly
55
56

1
2
3 towards enhancing the clinical management of peripheral neuropathy. A therapeutic
4 agent to prevent the pathogenesis of, or slow the progression of, peripheral nerve
5 damage has the potential to greatly improve clinical outcomes. Furthermore, the
6 potential for omega-3 PUFA supplements to alleviate neuropathy-associated
7 symptoms would be predicted to reduce impairment on an individual's quality of life
8 and lessen the economic burden of peripheral neuropathy in the community.
9
10
11
12
13
14
15
16
17

18 **OBJECTIVES**

19
20 The primary objective of this systematic review is to evaluate the efficacy and safety
21 of oral omega-3 PUFA supplements for improving peripheral nerve health. Efficacy
22 outcomes will consider both subjective endpoints (i.e., symptoms) and objective
23 clinical measures, including changes to peripheral nerve structure and function.
24
25
26
27
28
29
30

31 **METHODS AND ANALYSIS**

32
33 We will conduct the proposed systematic review and meta-analyses according to the
34 recommendations stated in the *Cochrane Handbook for Systematic Reviews of*
35 *Interventions*,^[53] and following the Preferred Reporting Items for Systematic
36 Reviews and Meta Analyses (PRISMA) statement.^[54] The protocol for this review
37 will be prospectively published on the PROSPERO online registry.
38
39
40
41
42
43
44
45
46

47 **Eligibility criteria**

48
49 All studies published from the date of database inception until 21st November 2017
50 will be included. Studies will be selected according to the following eligibility
51 criteria:
52
53
54
55
56
57
58
59
60

Types of studies

We will include randomised controlled trials (RCTs) where participants were allocated to consume oral omega-3 PUFA supplements. We will exclude quasi-randomised trials. We will not exclude studies based upon language, publication status, year, or the number of participants. In cases where more than one publication reporting data from the same cohort of participants exist (i.e., from the same trial), the study reporting on the largest number of participants will be included. Published conference abstracts will be eligible for inclusion.

Types of participants

We will include studies involving adults (i.e., aged 18 years or older), recruited from within any study setting, where the structure and/or function of peripheral nerves was assessed. To be eligible for inclusion in the review, studies need to include at least one subjective measure of peripheral neuropathy (e.g., symptom score), one composite measure of peripheral neuropathy (i.e., combining subjective and objective measures), or one objective measure of peripheral nerve structure (e.g., nerve biopsy) or function (e.g., nerve conduction studies).

Types of interventions

We will consider interventions where participants were randomised to oral supplementation with short-chain and/or long-chain omega-3 PUFAs. We will accept studies that administered omega-3 supplements in any form or dosage. We will exclude studies where the intervention was administered in the form of dietary manipulation (i.e., a food-based intervention), and where omega-3 PUFA supplements were administered in combination with another intervention (including other

1
2
3 nutritional interventions), unless the intervention was administered in the same dose
4 and frequency in the comparator group. We will consider studies where omega-3
5 PUFA supplements were compared to placebo or no treatment.
6
7
8
9

10 11 **Types of outcome measures**

12
13 There are no gold standard or universally accepted outcome measures for peripheral
14 nerve assessment. In selecting the outcome measures for this review, we considered
15 the recommendations provided by the European Neuromuscular Centre (ENMC)
16 International workshop: Selection of Outcome Measures for Peripheral Neuropathy
17 Clinical Trials (10-12 December 2014), taking into account both subjective and
18 clinical measures.[55]
19
20
21
22
23
24
25
26
27
28

29 We will assess all outcome measures at six months of follow-up, with an acceptable
30 follow-up range of between three and nine months from baseline. If studies do not
31 report the change from baseline, we will utilise data reported at the end of the follow-
32 up period.
33
34
35
36
37
38
39

40 **Primary outcomes**

41
42 The primary outcome will be the change, from baseline, in peripheral neuropathy
43 impairments, as quantified by validated, composite (i.e., combining symptoms plus
44 objective measures) neuropathy measures. We have not been prescriptive in our
45 selection of particular scales as there are no universally agreed scoring systems;
46 examples of validated, composite neuropathy assessment scales include the Michigan
47 Diabetic Neuropathy Score (MDNS),[56] Neuropathy Impairment Score (NIS)[57]
48
49
50
51
52
53
54
55
56
57
58
59
60

and Total Neuropathy Score (TNS).[58] For the purpose of this review, we define a ‘validated’ measure being a survey instrument that has been psychometrically tested.

Secondary outcomes

We will consider the following secondary outcomes:

1. Symptoms: change, from baseline, in symptoms of peripheral neuropathy, measured by a validated, patient-assessed symptom score;
2. Pain: change, from baseline, in mean scores of pain, measured by a validated, patient-assessed pain scale. Examples of validated scales include the visual analogue scale (VAS),[59] Likert scales[60, 61] and the McGill Pain Questionnaire (MPQ).[62]
3. Disability: change, from baseline, in the mean score of a patient-reported disability measure. Examples of validated disability measures include the Overall Neuropathy Limitation Scale[63] and the Overall Disability Sum Score (ODSS).[64]
4. Anatomical markers:
 - a. Change, from baseline in central corneal nerve fibre length (CNFL), defined as the total length of nerves in a given area, measured in mm/mm², using a laser-scanning in vivo confocal microscope (IVCM);
 - b. Change, from baseline in intraepidermal nerve fibre density (IENFD).
5. Nerve Conduction Studies (NCS): Change, from baseline, in nerve conduction study parameters, as recommended by England (2005):[65]
 - a. Sensory nerve action potential (SNAP) amplitudes of the sural, median and ulnar nerves;
 - b. SNAP latencies of the sural, median and ulnar nerves;

- c. Sensory nerve conduction velocity (NCV) of the sural, median and ulnar nerves;
 - d. Distal compound motor action potential (CMAP) amplitude of the peroneal, tibial, median and ulnar nerves;
 - e. CMAP latency of the peroneal, tibial, median and ulnar nerves;
 - f. Motor NCV of the peroneal and ulnar Motor NCV of the peroneal, tibial, medium and ulnar nerves;
 - g. Minimum F-wave latency of the peroneal, tibial, median and ulnar nerves.
6. Sensory function in the cornea: change, from baseline, in corneal sensation, as quantified using:
- a. Contact aesthesiometry, to quantify mechanical detection thresholds using the Cochet-Bonnet aesthesiometer (measured in millimetres);
 - b. Non-contact aesthesiometry, to quantify corneal sensation quantified using an air-based aesthesiometer (measured in millibars).
7. Sensory function in the skin: Change, from baseline, in sensory function test scores:
- a. Mechanical detection thresholds, measured using pressure aesthesiometry (e.g., von Frey hair aesthesiometer);
 - b. Cold detection thresholds measured using quantitative sensory testing (QST) methods;
 - c. Warm detection thresholds measured using QST methods;
 - d. Thermal pain thresholds, for cold and hot stimuli, measured using QST methods.

- 1
2
3 8. Adverse events: we will consider all adverse events, and will analyse them in
4 the following categories: (i) any adverse events, (ii) adverse events leading to
5 discontinuation of the interventions, and (iii) serious adverse events, being
6 those leading to hospitalization or prolonged admission, a life-threatening
7 event or death.
8
9
10
11
12
13
14
15

16 **Search methods for identification of studies**

17
18 We will conduct comprehensive electronic database searches in: the Cochrane Central
19 Register of Controlled Trials (CENTRAL) (Issue 10, October 2017), Ovid
20 MEDLINE, Ovid MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed
21 Citations, Ovid MEDLINE Daily (January 1946 to November 2017), EMBASE
22 (January 1947 to November 2017). We will also search the US National Institutes of
23 Health Clinical Trials Registry (www.clinicaltrials.gov) and the World Health
24 Organization (WHO) International Clinical Trials Registry Platform (ICTRP)
25 (www.who.int/ictcp/en/). We will not impose any restrictions on date or language in
26 our search strategies. Search strategies for all electronic searches are included in
27 Appendices 1 – 5. We will additionally search the bibliographies of included RCTs to
28 identify any other potentially relevant studies.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 **Data collection and analysis**

45
46 After the search strategies are performed within each electronic database, the
47 reference lists will be imported into EndNote. Duplicate entries will be identified and
48 removed. The final reference library will be imported into Covidence,[66] the
49 standard production platform for Cochrane reviews, for the study selection process.
50
51
52
53
54
55
56
57
58
59
60

Selection of studies

The titles, keywords and abstracts of all unique articles, identified by the search strategies, will be independently reviewed by two review authors to identify potentially eligible studies. The full text papers of articles identified as relevant or potentially relevant, by at least one reviewer, will be retrieved for full text screening. Full text articles will be independently screened by two review authors and assessed for eligibility according to the pre-specified inclusion and exclusion criteria. Reasons for exclusion will be identified and recorded for ineligible studies that progress to the full text screening stage. Any disagreements in eligibility assessment will be adjudicated between the two reviewers; if consensus cannot be achieved, a third independent author will be consulted to reach consensus. We will include a PRISMA flow diagram (summarising the article selection process) and a 'Characteristics of excluded studies' table (with reasons for study exclusion).

Data extraction and management

Two review authors will independently extract outcome data and key study characteristics for all included studies. Any discrepancies will be resolved by discussion and consensus. We will contact the study authors of relevant trials, by email, if further information or clarification is required. If we fail to receive a response from the corresponding author within four weeks, or if the authors are unable to provide us with the requested information, we will use the information that is available.

For each study, we will extract the following information:

1. Article details: year of publication, journal of publication, language, publication status;
2. Study details: dates study conducted, trial registration number, country, study setting, corresponding author details (name, institution, email, address) and whether the study investigators were contacted for further information;
3. Methods: exclusions after randomisation, losses to follow-up, how missing data were handled, whether a sample size calculation was reported;
4. Participants: number of participants in each intervention group, participant baseline characteristics (i.e., age, gender and/or sex (as specified by the study authors), underlying conditions, peripheral neuropathy diagnostic criteria), participant inclusion criteria and exclusion criteria, comparison of groups at baseline;
5. Interventions: intervention(s) and comparator (type (long- or short-chain), dose (milligrams/day), duration of treatment), concomitant medications or treatments;
6. Outcomes: pre-specified primary and secondary outcome measures, time points of assessments;
7. Other: sources of funding statement (i.e., present or absent), actual source of funding (e.g., industry funding), conflicts of interest statement (i.e., present or absent), nature of conflict of interest (e.g., industry employee).

Assessment of risk of bias in included studies

Two review authors will independently assess the risk of bias for each included study using *the Cochrane Handbook for Systematic Reviews* guidelines. Assessment of bias will be considered using the following domains:

1. Selection bias (random sequence generation and allocation concealment);
2. Performance bias (blinding of participants and all study personnel);
3. Detection bias (blinding of outcome assessors);
4. Attrition bias (incomplete outcome data);
5. Reporting bias (selective reporting of outcomes);
6. Other sources of bias (funding source, conflicts of interest).

Each review author will judge the risk of bias in each domain as: (i) low risk, (ii) unclear risk or (iii) high risk. Disagreements in bias assessment will be resolved by consensus between the two reviewers.

Measures of treatment effect

We will analyse data according to the methods described in Chapter 9 of the *Cochrane Handbook for Systematic Reviews of Interventions*.^[53]

As all of the pre-defined outcomes are continuous measures, we will extract information on the change in mean from baseline, and standard deviations of change, for the intervention and comparison groups. If change from baseline is not reported, we will extract information on the mean and standard deviation of the outcome, for the intervention and comparator groups, at the specified follow-up period. The effects of the interventions will be expressed as the mean difference (MD), with 95% confidence intervals (CIs), between the intervention and comparator groups.

Unit of analysis issues

The unit of analysis for this review will be the individual participant. In studies where outcomes were measured in ocular tissues, the unit of analysis will be the enrolled study eye of the participant. In studies where participants were randomly allocated to treatment, there will be no unit of analysis issues if only one eye per person is included in the trial, or if both eyes per person are included and the average value of both eyes are reported. In studies where participants were randomly allocated to treatment and both eyes were included, but reported separately, we will analyse this as clustered data (i.e. adjusted for within-person correlation). We may have to contact the trial investigators for further information to do this.

Dealing with missing data

For any studies where missing outcome data (e.g., omitted standard deviations, standard errors) are identified, we will attempt to contact the study authors. If we fail to receive a response from the corresponding authors in four weeks, or if the authors are unable to provide us with the requested information, we will use the information that is available. We will use imputed data, if this has been derived by the trial investigators using an appropriate method, but will not impute missing data ourselves.

Assessment of heterogeneity

We will assess clinical and methodological heterogeneity in the included studies by examining differences in the intervention (e.g., type, dose, form), participant characteristics at baseline (e.g., age, gender/sex, cause of neuropathy, eligibility criteria, etc.), and risk of bias. We will quantify statistical heterogeneity using the I^2 statistic, as outlined in Chapter 9 of the *Cochrane Handbook for Systematic Reviews*

1
2
3 *of Interventions*;^[53] we will consider an I^2 statistic of 60% or more as consistent with
4 a moderate level of heterogeneity. In measuring heterogeneity, we will also consider
5 the: (i) magnitude and direction of the effects of individual studies, and (ii) strength of
6 evidence for heterogeneity (using a p-value < 0.10 from the Chi-squared test as the
7 criterion for significant heterogeneity).
8
9
10
11
12

13 14 15 16 **Assessment of reporting biases**

17
18 If at least ten studies are included in a meta-analysis, we will use a funnel plot to
19 assess for any potential publication bias. We will interpret any asymmetries in the
20 funnel plot in association with the trial characteristics, considering relevant factors
21 such as sample size.
22
23
24
25
26
27
28

29 **Data synthesis**

30
31
32 We will undertake meta-analyses, for the primary and/or secondary outcomes, when
33 this would be clinically meaningful (i.e., for studies where the treatment, participants
34 and the underlying clinical questions are similar). If fewer than three RCTs are to be
35 included in a meta-analysis, we will use a fixed-effect model, otherwise we will use a
36 random-effects model.
37
38
39
40
41
42
43
44

45
46 If there is inconsistency between individual study results, such that the pooled results
47 may not provide a fair representation of the trial findings (e.g., the effects are in
48 opposite directions, or $I^2 > 60\%$ or the Chi-squared test p-value is <0.10), we will not
49 pool the study data but will instead describe the pattern of the individual study results.
50
51
52

53
54 If there is statistical heterogeneity but all of the effect estimates are in the same
55
56
57
58
59
60

1
2
3 direction, such that a pooled estimate would seem to provide a good summary of the
4
5 individual trial results, we may pool the data.
6
7

8 If a meta-analysis is not deemed appropriate, we will provide a descriptive or
9
10 tabulated results summary.
11
12
13

14 **Subgroup analysis and investigation of heterogeneity**

15
16 If sufficient data are available, we will perform subgroup analyses by prognostic
17
18 factors (e.g., severity of peripheral neuropathy at baseline, and age) and by potential
19
20 intervention effect modifiers (e.g., dose, duration and type of omega-3 PUFA
21
22 supplement), as these factors are potentially important to any observed treatment
23
24 effects.
25
26
27
28
29

30 **Sensitivity analysis**

31
32 Provided there are sufficient data available, we will perform a sensitivity analysis for
33
34 the primary outcome (i.e., change in peripheral neuropathy impairment score), to
35
36 assess the impact of excluding studies that: i) were appraised as having a high risk of
37
38 bias due to lack of allocation concealment or lack of blinding of participants and
39
40 study personnel, ii) had more than 20 percent of participants that were lost to follow-
41
42 up, iii) were unpublished, and iv) were funded by industry.
43
44
45
46
47

48 **Summary of findings table**

49
50 Provided that sufficient data are available, we will provide a “Summary of findings”
51
52 table for the primary outcome (change in peripheral neuropathy as measured using a
53
54 validated composite neuropathy assessment) and the following secondary outcomes
55
56
57
58
59
60

(as previously defined): (i) Symptoms, (ii) Pain, (iii) Corneal nerve fibre length (CNFL), (iv) Intraepidermal nerve fibre density (IENFD), (v) SNAP amplitudes of the sural nerve, and (vi) Motor NCV of the peroneal nerve. We will follow the recommendations specified in Chapter 11 of the *Cochrane Handbook for Systematic Reviews of Interventions*.^[53] The strength and quality of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.^[67]

CONCLUSIONS

The term “peripheral neuropathy” describes a heterogeneous group of disorders that cause damage to the peripheral nervous system. Currently, management approaches for peripheral neuropathy are aimed primarily at addressing the underlying cause and/or managing symptoms. For many causes of peripheral neuropathy, including diabetes, reversing or even limiting the progression of nerve damage remains a challenge with currently available therapeutics.

Omega-3 PUFAs are reported to be associated with a range of general health benefits that include reducing the risk of cardiovascular disease,^[35, 36] lowering systemic triglycerides^[37] and improving clinical symptoms of dry eye disease.^[41] In animal models of experimental peripheral nerve injury, increasing endogenous levels of omega-3 PUFAs have been shown to improve sciatic blood flow and accelerate the recovery of neuronal function.^[47, 49, 50]

The aim of this systematic review is to assess the safety and efficacy of oral omega-3 PUFA supplementation for improving peripheral nerve health. If it is demonstrated

1
2
3 that omega-3 supplements can improve measures of peripheral nerve function and/or
4
5 quality of life, it is anticipated that this therapy would make a valuable contribution to
6
7 the current clinical management of peripheral neuropathy.
8
9

10 11 **AUTHORS' CONTRIBUTIONS**

12
13 All authors (ACZ, LED, LB, JK, RJM, LR and JPC) made contributions to the
14
15 conception and/or design of the work; and drafted (ACZ and LED) or revised (LB,
16
17 JK, RJM, LR and JPC) the protocol; and approved the final version of the manuscript;
18
19 and agree to be accountable for all aspects of the submitted work.
20
21
22
23

24 25 **FUNDING STATEMENT**

26
27 This work was supported by 2018 Melbourne Neuroscience Institute (MNI)
28
29 Interdisciplinary Seed Funding (LED, RJM, LR, JK); the funder had no role in the
30
31 design of this protocol and will not have any role in the undertaking, data analyses, or
32
33 reporting of the systematic review.
34
35
36
37

38 39 **COMPETING INTERESTS STATEMENT**

40
41 All authors declare no conflicts of interest relevant to this review.
42
43
44

45 46 **ACKNOWLEDGEMENTS**

47
48 We acknowledge the advice of Iris Gordon, Cochrane Eyes and Vision Group, who
49
50 provided feedback on the search strategies for this review.
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Hughes RA. Peripheral neuropathy. *BMJ*. 2002;324(7335):466-9.
2. England JD, Asbury AK. Peripheral neuropathy. *Lancet*. 2004;363(9427):2151-61.
3. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. *Lancet Neurol*. 2012;11(6):521-34.
4. Cameron NE, Cotter MA. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. *Curr Drug Targets*. 2008;9(1):60-7.
5. Cashman CR, Hoke A. Mechanisms of distal axonal degeneration in peripheral neuropathies. *Neurosci Lett*. 2015;596:33-50.
6. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. *Neurology*. 1993;43(4):817-24.
7. Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. *Diabetes Care*. 2014;37(1):9-16.
8. Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. *J Neurol Neurosurg Psychiatry*. 1997;62(4):310-8.
9. Gordon Smith A, Robinson Singleton J. Idiopathic neuropathy, prediabetes and the metabolic syndrome. *J Neurol Sci*. 2006;242(1-2):9-14.

10. Sommer CL, Brandner S, Dyck PJ, Harati Y, LaCroix C, Lammens M, et al. Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies. *J Periph Nerv Syst*. 2010;15(3):164-75.
11. Mallik A, Weir AI. Nerve conduction studies: essentials and pitfalls in practice. *J Neurol Neurosurg Psychiatry*. 2005;76(suppl 2):ii23-ii31.
12. Dyck PJ, Karnes JL, Daube J, O'Brien P, Service FJ. Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. *Brain*. 1985;108 (Pt 4):861-80.
13. Azhary H, Farooq MU, Bhanushali M, Majid A, Kassab MY. Peripheral neuropathy: differential diagnosis and management. *Am Fam Physician*. 2010;81(7):887-92.
14. Lauria G, Lombardi R. Skin biopsy: a new tool for diagnosing peripheral neuropathy. *BMJ*. 2007;334(7604):1159-62.
15. Hoeijmakers JG, Faber CG, Lauria G, Merkies IS, Waxman SG. Small-fibre neuropathies--advances in diagnosis, pathophysiology and management. *Nat Rev Neurol*. 2012;8(7):369-79.
16. Floeter MK. Cutaneous silent periods. *Muscle & nerve*. 2003;28(4):391-401.
17. Sletten DM, Weigand SD, Low PA. Relationship of Q-sweat to quantitative sudomotor axon reflex test (QSART) volumes. *Muscle Nerve*. 2010;41(2):240-6.
18. Kamel JT, Vogrin SJ, Knight-Sadler RJ, Willems NK, Seiderer L, Cook MJ, et al. Combining cutaneous silent periods with quantitative sudomotor axon reflex testing in the assessment of diabetic small fiber neuropathy. *Clin Neurophysiol*. 2015;126(5):1047-53.
19. De Silva MEH, Zhang AC, Karahalios A, Chinnery HR, Downie LE. Laser scanning in vivo confocal microscopy (IVCM) for evaluating human corneal sub-

1
2
3 basal nerve plexus parameters: protocol for a systematic review. *BMJ Open*.
4
5 2017;7(11):e018646.

6
7 20. Quattrini C, Tavakoli M, Jeziorska M, Kallinikos P, Tesfaye S, Finnigan J, et
8
9 al. Surrogate markers of small fiber damage in human diabetic neuropathy. *Diabetes*.
10
11 2007;56(8):2148-54.

12
13
14 21. Ferdousi M, Azmi S, Petropoulos IN, Fadavi H, Ponirakis G, Marshall A, et
15
16 al. Corneal Confocal Microscopy Detects Small Fibre Neuropathy in Patients with
17
18 Upper Gastrointestinal Cancer and Nerve Regeneration in Chemotherapy Induced
19
20 Peripheral Neuropathy. *PloS One*. 2015;10(10):e0139394.

21
22 22. Asghar O, Petropoulos IN, Alam U, Jones W, Jeziorska M, Marshall A, et al.
23
24 Corneal confocal microscopy detects neuropathy in subjects with impaired glucose
25
26 tolerance. *Diabetes Care*. 2014;37(9):2643-6.

27
28 23. Tavakoli M, Marshall A, Thompson L, Kenny M, Waldek S, Efron N, et al.
29
30 Corneal confocal microscopy: a novel noninvasive means to diagnose neuropathy in
31
32 patients with Fabry disease. *Muscle Nerve*. 2009;40(6):976-84.

33
34 24. Sturniolo GC, Lazzarini D, Bartolo O, Berton M, Leonardi A, Fregona IA, et
35
36 al. Small fiber peripheral neuropathy in Wilson disease: an in vivo documentation by
37
38 corneal confocal microscopy. *Invest Ophthalmol Vis Sci*. 2015;56(2):1390-5.

39
40 25. Tavakoli M, Mitu-Pretorian M, Petropoulos IN, Fadavi H, Asghar O, Alam U,
41
42 et al. Corneal confocal microscopy detects early nerve regeneration in diabetic
43
44 neuropathy after simultaneous pancreas and kidney transplantation. *Diabetes*.
45
46 2013;62(1):254-60.

47
48 26. Tavakoli M, Kallinikos P, Iqbal A, Herbert A, Fadavi H, Efron N, et al.
49
50
51 Corneal confocal microscopy detects improvement in corneal nerve morphology with
52
53

- 1
2
3 an improvement in risk factors for diabetic neuropathy. *Diabet Med*.
4 2011;28(10):1261-7.
5
6
7 27. Pritchard N, Edwards K, Dehghani C, Fadavi H, Jeziorska M, Marshall A, et
8 al. Longitudinal assessment of neuropathy in type 1 diabetes using novel ophthalmic
9 markers (LANDMark): study design and baseline characteristics. *Diabet Res Clin*
10 *Practice*. 2014;104(2):248-56.
11
12
13 28. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic Somatic
14 Neuropathies. *Diabetes Care*. 2004;27(6):1458-86.
15
16 29. Alleman CJ, Westerhout KY, Hensen M, Chambers C, Stoker M, Long S, et
17 al. Humanistic and economic burden of painful diabetic peripheral neuropathy in
18 Europe: A review of the literature. *Diabetes Res Clin Pract*. 2015;109(2):215-25.
19
20 30. Mehra M, Merchant S, Gupta S, Potluri RC. Diabetic peripheral neuropathy:
21 resource utilization and burden of illness. *J Med Econ*. 2014;17(9):637-45.
22
23 31. McCarberg BH, Billington R. Consequences of neuropathic pain: quality-of-
24 life issues and associated costs. *Am J Manag Care*. 2006;12(9 Suppl):S263-8.
25
26 32. Nettleton JA. Omega-3 fatty acids: comparison of plant and seafood sources in
27 human nutrition. *J Am Diet Assoc*. 1991;91(3):331-7.
28
29 33. Calder PC, Grimble RF. Polyunsaturated fatty acids, inflammation and
30 immunity. *Eur J Clin Nutr*. 2002;56 Suppl 3:S14-9.
31
32 34. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential
33 fatty acids. *Biomed Pharmacother*. 2002;56(8):365-79.
34
35 35. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in
36 cardiovascular disease and other chronic diseases. *Exp Biol Med*. 2008;233(6):674-
37 88.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 36. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y,
4 et al. Effects of eicosapentaenoic acid on major coronary events in
5 hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint
6 analysis. *Lancet*. 2007;369(9567):1090-8.
7
8
9
10
11 37. Chauhan S, Kodali H, Noor J, Ramteke K, Gawai V. Role of Omega-3 Fatty
12 Acids on Lipid Profile in Diabetic Dyslipidaemia: Single Blind, Randomised Clinical
13 Trial. *J Clin Diagn Res*. 2017;11(3):Oc13-oc6.
14
15
16
17 38. Hibbeln JR, Davis JM, Steer C, Emmett P, Rogers I, Williams C, et al.
18 Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in
19 childhood (ALSPAC study): an observational cohort study. *Lancet*.
20 2007;369(9561):578-85.
21
22
23
24
25 39. McNamara RK. DHA deficiency and prefrontal cortex neuropathology in
26 recurrent affective disorders. *J Nutr*. 2010;140(4):864-8.
27
28
29
30
31 40. Birch EE, Hoffman DR, Uauy R, Birch DG, Prestidge C. Visual acuity and the
32 essentiality of docosahexaenoic acid and arachidonic acid in the diet of term infants.
33 *Ped Res*. 1998;44(2):201-9.
34
35
36
37 41. Deinema LA, Vingrys AJ, Wong CY, Jackson DC, Chinnery HR, Downie LE.
38 A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of
39 Omega-3 Supplements for Treating Dry Eye Disease. *Ophthalmology*.
40 2017;124(1):43-52.
41
42
43
44
45 42. Kris-Etherton PM, Harris WS, Appel LJ. Fish Consumption, Fish Oil, Omega-
46 3 Fatty Acids, and Cardiovascular Disease. *Circulation*. 2002;106(21):2747-57.
47
48
49
50
51 43. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al.
52 Triglycerides and Cardiovascular Disease. A Scientific Statement From the American
53 Heart Association. 2011;123(20):2292-333.
54
55
56
57
58
59
60

- 1
2
3 44. Gibney MJ, Hunter B. The effects of short- and long-term supplementation
4 with fish oil on the incorporation of n-3 polyunsaturated fatty acids into cells of the
5 immune system in healthy volunteers. *Eur J Clin Nutr.* 1993;47(4):255-9.
6
7
8
9 45. Coste TC, Gerbi A, Vague P, Pieroni G, Raccach D. Neuroprotective effect of
10 docosahexaenoic acid-enriched phospholipids in experimental diabetic neuropathy.
11 *Diabetes.* 2003;52(10):2578-85.
12
13
14
15 46. Kitajka K, Sinclair AJ, Weisinger RS, Weisinger HS, Mathai M, Jayasooriya
16 AP, et al. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene
17 expression. *Proc Natl Acad Sci USA.* 2004;101(30):10931-6.
18
19
20
21
22 47. Gerbi A, Maixent JM, Ansaldi JL, Pierlovisi M, Coste T, Pelissier JF, et al.
23 Fish oil supplementation prevents diabetes-induced nerve conduction velocity and
24 neuroanatomical changes in rats. *J Nutr.* 1999;129(1):207-13.
25
26
27
28
29 48. Yee P, Weymouth AE, Fletcher EL, Vingrys AJ. A role for omega-3
30 polyunsaturated fatty acid supplements in diabetic neuropathy. *Invest Ophthalmol Vis*
31 *Sci.* 2010;51(3):1755-64.
32
33
34
35 49. Gladman SJ, Huang W, Lim SN, Dyall SC, Boddy S, Kang JX, et al.
36 Improved outcome after peripheral nerve injury in mice with increased levels of
37 endogenous omega-3 polyunsaturated fatty acids. *J Neurosci.* 2012;32(2):563-71.
38
39
40
41
42 50. Robson LG, Dyall S, Sidloff D, Michael-Titus AT. Omega-3 polyunsaturated
43 fatty acids increase the neurite outgrowth of rat sensory neurones throughout
44 development and in aged animals. *Neurobiol Aging.* 2010;31(4):678-87.
45
46
47
48
49 51. Cortina MS, He J, Russ T, Bazan NG, Bazan HE. Neuroprotectin D1 restores
50 corneal nerve integrity and function after damage from experimental surgery. *Invest*
51 *Ophthalmol Vis Sci.* 2013;54(6):4109-16.
52
53
54
55
56
57
58
59
60

- 1
2
3 52. Xu ZZ, Liu XJ, Berta T, Park CK, Lu N, Serhan CN, et al.
4 Neuroprotectin/protectin D1 protects against neuropathic pain in mice after nerve
5 trauma. *Ann Neurol*. 2013;74(3):490-5.
6
7
8
9 53. Higgins J, Green S, (editors). *Cochrane Handbook for Systematic Reviews of*
10 *Interventions Version 5.1.0: The Cochrane Collaboration*; 2011 (updated March
11 2011). Available from: <http://handbook.cochrane.org>.
12
13
14
15 54. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
16 systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*.
17 2009;151(4):264-9.
18
19
20
21 55. Merkies IS, Lauria G. 131st ENMC international workshop: selection of
22 outcome measures for peripheral neuropathy clinical trials 10-12 December 2004,
23 Naarden, The Netherlands. *Neuromuscular disord*. 2006;16(2):149-56.
24
25
26
27 56. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A
28 Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the
29 Diagnosis and Staging of Diabetic Neuropathy. *Diabetes Care*. 1994;17(11):1281-9.
30
31
32
33 57. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC.
34 Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy
35 Study of Healthy Subjects. *Neurology*. 1995;45(6):1115-21.
36
37
38
39 58. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, et
40 al. Total neuropathy score: validation and reliability study. *Neurology*.
41 1999;53(8):1660-4.
42
43
44
45 59. Wewers ME, Lowe NK. A critical review of visual analogue scales in the
46 measurement of clinical phenomena. *Res Nurs Health*. 1990;13(4):227-36.
47
48
49
50 60. Hasson D, Arnetz B. Validation and Findings Comparing VAS vs. Likert
51 Scales for Psychosocial Measurements. *Int Electronic J Health Educ*. 2005; 8:178-92.
52
53
54
55
56
57
58
59
60

- 1
2
3 61. Farrar JT, Young JP, Jr., LaMoreaux L, Werth JL, Poole RM. Clinical
4 importance of changes in chronic pain intensity measured on an 11-point numerical
5 pain rating scale. *Pain*. 2001;94(2):149-58.
6
7
8
9 62. Melzack R. The McGill Pain Questionnaire: major properties and scoring
10 methods. *Pain*. 1975;1(3):277-99.
11
12
13 63. Graham RC, Hughes RAC. A modified peripheral neuropathy scale: the
14 Overall Neuropathy Limitations Scale. *J Neurol Neurosurg Psychiatry*.
15 2006;77(8):973-6.
16
17
18 64. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA.
19 Clinimetric evaluation of a new overall disability scale in immune mediated
20 polyneuropathies. *J Neurol Neurosurg Psychiatry*. 2002;72(5):596-601.
21
22
23
24
25 65. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, et
26 al. Distal symmetric polyneuropathy: a definition for clinical research: report of the
27 American Academy of Neurology, the American Association of Electrodiagnostic
28 Medicine, and the American Academy of Physical Medicine and Rehabilitation.
29 *Neurology*. 2005;64(2):199-207.
30
31
32
33
34
35
36
37 66. Covidence systematic review software Melbourne, Australia.: Veritas Health
38 Innovation; [cited 2017 November]. Available from: www.covidence.org.
39
40
41
42 67. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R,
43 Singh JA, et al. A GRADE Working Group approach for rating the quality of
44 treatment effect estimates from network meta-analysis. *BMJ*. 2014;349:g5630.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

APPENDIX 1

MEDLINE (OViD) search strategy

Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to November 2017

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. (randomised OR randomized).ab,ti.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp Diabetic Neuropathies/
13. exp Diabetic Foot/
14. exp Peripheral Nervous System Diseases/
15. neuropath*.tw.
16. exp Neuralgia/

- 1
- 2
- 3 17. neuralgia.tw.
- 4
- 5 18. exp Charcot-Marie-Tooth Disease/
- 6
- 7
- 8 19. exp Facial Nerve Diseases/
- 9
- 10
- 11 20. exp Nerve Regeneration/
- 12
- 13
- 14 21. exp Nerve Degeneration/
- 15
- 16 22. nerve*.tw.
- 17
- 18
- 19 23. exp Hyperalgesia/
- 20
- 21
- 22 24. allodynia.tw.
- 23
- 24
- 25 25. exp Sensation/
- 26
- 27
- 28 26. sensation.tw.
- 29
- 30
- 31 27. exp Sensation Disorders/
- 32
- 33 28. an?esthesiomet*.tw.
- 34
- 35
- 36 29. esthesiomet*.tw.
- 37
- 38
- 39 30. aesthesiomet*.tw.
- 40
- 41
- 42 31. (guillain and barre).tw.
- 43
- 44
- 45 32. (polyradiculoneuritis OR polyradiculoneuropath* OR polyradiculopath*).tw.
- 46
- 47 33. (inflammatory adj3 (polyneuropath* OR mononeuropath* OR
- 48 polyradiculoneuropath*).tw.
- 49
- 50
- 51
- 52 34. (amyloid adj3 neuropath*).tw.
- 53
- 54
- 55 35. (motor and sensory and neuropath* and hereditary).mp.
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3 36. (hereditary and sensory and autonomic and neuropath*).mp.
- 4
- 5 37. (heredit* adj6 neuropath*).mp.
- 6
- 7
- 8 38. or/12-37
- 9
- 10
- 11 39. (omega-3 OR omega 3).tw.
- 12
- 13
- 14 40. (PUFA* OR LCPUFA* OR polyunsaturated OR poly-unsaturated).tw.
- 15
- 16
- 17 41. eicosapentaenoic.tw.
- 18
- 19 42. EPA.tw.
- 20
- 21
- 22 43. docosahexaenoic.tw.
- 23
- 24
- 25 44. DHA.tw.
- 26
- 27
- 28 45. exp Alpha-Linolenic Acid/
- 29
- 30
- 31 46. alpha-linolenic.tw.
- 32
- 33
- 34 47. Fatty acids/
- 35
- 36 48. Fatty Acids, Unsaturated/
- 37
- 38
- 39 49. Fatty Acids, Essential/
- 40
- 41
- 42 50. exp Fatty Acids, Omega-3/
- 43
- 44
- 45 51. (Fatty adj3 acid*).tw.
- 46
- 47 52. or/39-51
- 48
- 49
- 50 53. 11 and 38 and 52
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

APPENDIX 2

EMBASE (OviD) search strategy*Embase Classic + Embase 1947 to November 2017*

1. exp Randomized Controlled Trial/
2. Exp controlled clinical trial
3. (randomised OR randomized).ab,ti.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp neuropathy/
13. exp neuralgia/
14. exp nerve regeneration/
15. exp peripheral nervous system/
16. neuropath*.tw.
17. neuralgia.tw.
18. nerve*

19. an?esthesiomet*.tw.
20. esthesiomet*.tw.
21. aesthesiomet*.tw.
22. sensation*.tw.
23. exp sensation/
24. exp hyperalgesia/
25. exp allodynia/
26. hyperalgesia.tw.
27. allodynia.tw.
28. (guillain and barre).tw.
29. (polyradiculoneuritis OR polyradiculoneuropath* OR polyradiculopath*).tw.
30. (inflammatory adj3 (polyneuropath* OR mononeuropath* OR polyradiculoneuropath*)).tw.
31. (amyloid adj3 neuropath*).tw.
32. (motor and sensory and neuropath* and hereditary).mp.
33. (hereditary and sensory and autonomic and neuropath*).mp.
34. (heredit* adj6 neuropath*).mp.
35. or/12-34
36. exp unsaturated fatty acid/
37. exp fish oil/

- 1
- 2
- 3 38. (PUFA* OR LCPUFA* OR polyunsaturated OR poly-unsaturated).tw.
- 4
- 5 39. (omega-3 OR omega 3).tw.
- 6
- 7
- 8 40. eicosapentaenoic.tw.
- 9
- 10
- 11 41. docosahexaenoic.tw.
- 12
- 13
- 14 42. alpha-linolenic.tw.
- 15
- 16 43. (Fatty adj3 acid*).tw.
- 17
- 18
- 19 44. EPA.tw.
- 20
- 21
- 22 45. DHA.tw.
- 23
- 24
- 25 46. or/36-45
- 26
- 27
- 28 47. 11 and 35 and 46
- 29
- 30
- 31
- 32

APPENDIX 3

Cochrane Central Register of controlled Trials (CENTRAL) search strategy

- 33
- 34
- 35
- 36
- 37
- 38
- 39 1. MeSH descriptor: [Diabetic Neuropathies] explode all trees
- 40
- 41
- 42 2. MeSH descriptor: [Diabetic Foot] explode all trees
- 43
- 44
- 45 3. MeSH descriptor: [Peripheral Nervous System Diseases] explode all trees
- 46
- 47
- 48 4. MeSH descriptor: [Neuralgia] explode all trees
- 49
- 50 5. MeSH descriptor: [Charcot-Marie-Tooth Disease] explode all trees
- 51
- 52
- 53 6. MeSH descriptor: [Facial Nerve Diseases] explode all trees
- 54
- 55
- 56 7. MeSH descriptor: [Nerve Regeneration] explode all trees
- 57
- 58
- 59
- 60

- 1
- 2
- 3 8. MeSH descriptor: [Nerve Degeneration] explode all trees
- 4
- 5 9. (neuropath* OR Neuralgia* OR nerve*):ti,ab,kw
- 6
- 7
- 8 10. MeSH descriptor: [Hyperalgesia] explode all trees
- 9
- 10
- 11 11. MeSH descriptor: [Sensation] explode all trees
- 12
- 13 12. MeSH descriptor: [Sensation Disorders] explode all trees
- 14
- 15 13. (sensation* OR hyperalgesia OR allodynia):ti,ab,kw
- 16
- 17 14. (an?esthesiomet* OR esthesiomet* OR aesthesiomet*):ti,ab,kw
- 18
- 19 15. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12
- 20
- 21 OR #13 OR #14
- 22
- 23
- 24 16. (omega-3 OR omega 3 OR ω-3 OR ω3 OR "ω 3"):ti,ab,kw
- 25
- 26
- 27 17. (PUFA* OR LCPUFA* OR polyunsaturated OR poly-unsaturated):ti,ab,kw
- 28
- 29
- 30 18. MeSH descriptor: [Eicosapentaenoic Acid] explode all trees
- 31
- 32 19. (Eicosapentaenoic OR EPA):ti,ab,kw
- 33
- 34 20. MeSH descriptor: [Docosahexaenoic Acids] explode all trees
- 35
- 36 21. (Docosahexaenoic OR DHA):ti,ab,kw
- 37
- 38 22. MeSH descriptor: [Alpha-Linolenic Acid] explode all trees
- 39
- 40 23. (Alpha-Linolenic):ti,ab,kw
- 41
- 42 24. MeSH descriptor: [Fatty acids] this term only
- 43
- 44 25. MeSH descriptor: [Fatty Acids, Unsaturated] this term only
- 45
- 46 26. MeSH descriptor: [Fatty Acids, Essential] this term only
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 27. MeSH descriptor: [Fatty Acids, Omega-3] explode all trees
4
5
6 28. (Fatty near/3 acid*):ti,ab,kw
7
8
9 29. #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR
10 #26 OR #27 OR #28
11
12
13 30. #15 and #29
14
15
16
17
18

19 APPENDIX 4

20 21 US National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov) search 22 strategy 23

24
25
26 Condition = neuropathy OR nerve OR sensation
27

28
29 Intervention = omega-3 OR “omega 3” OR polyunsaturated OR PUFA OR
30 “docosahexaenoic” OR DHA OR “eicosapentaenoic” OR EPA OR “fish oil” OR "fish-oil"
31
32
33

34 35 36 APPENDIX 5

37 38 39 World Health Organisation International Clinical Trials Registry Platform (WHO 40 ICTRP) search strategy (www.who.int/ictrp/) 41 42

43
44 Condition = nerve disorders OR nerve disease OR neuropathy OR nerve OR sensation
45

46
47 Intervention = omega-3 OR omega 3 OR polyunsaturated OR PUFA OR docosahexaenoic
48 OR eicosapentaenoic OR fish oil
49
50
51
52
53
54
55
56
57
58
59
60

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported in manuscript (page number + section details)
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	Not applicable
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	10 (methods and analysis)
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1 (title page)
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	23 (contribution of authors)
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	Not applicable
Support:			
Sources	5a	Indicate sources of financial or other support for the review	23 (funding statement)
Sponsor	5b	Provide name for the review funder and/or sponsor	23 (funding statement)
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	23 (funding statement)
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	5 (background)
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	10 (objectives)
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	10 (eligibility criteria)
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	15 (search methods for identification of studies)

Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	15 (search methods for identification of studies), appendix
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	16 (data collection and analysis)
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	16 (selection of studies)
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	17 (data extraction and management)
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	17 (data extraction and management)
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	12 (types of outcome measures)
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	18 (assessment of risk of bias in included studies)
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	21 (data synthesis)
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	21 (data synthesis)
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	20/21 (subgroup analysis and investigation of heterogeneity, sensitivity analysis)
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	21 (data synthesis)
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	20 (assessment of reporting biases)
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	22 (summary of findings table)

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (note when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

Omega-3 polyunsaturated fatty acid supplementation for improving peripheral nerve health: protocol for a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020804.R1
Article Type:	Protocol
Date Submitted by the Author:	20-Jan-2018
Complete List of Authors:	Zhang, Alexis; The University of Melbourne, Department of Optometry and Vision Sciences MacIsaac, Richard J.; St Vincent's Hospital Melbourne, Department of Endocrinology and Diabetes; The University of Melbourne, Department of Medicine Roberts, Leslie; The University of Melbourne, Department of Medicine; St Vincent's Hospital Melbourne, Centre for Clinical Neurosciences and Neurological Research Kamel, Jordan; The University of Melbourne, Department of Medicine; St Vincent's Hospital Melbourne, Centre for Clinical Neurosciences and Neurological Research Craig, Jennifer; University of Auckland, Department of Ophthalmology Busija, Lucy ; Australian Catholic University,, Institute for Health and Ageing Downie, Laura; The University of Melbourne, Department of Optometry and Vision Sciences
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Complementary medicine, Ophthalmology, Pharmacology and therapeutics
Keywords:	Diabetic neuropathy < DIABETES & ENDOCRINOLOGY, NEUROLOGY, Neuropathology < NEUROLOGY, THERAPEUTICS, COMPLEMENTARY MEDICINE, Adult neurology < NEUROLOGY

SCHOLARONE™
Manuscripts

Omega-3 polyunsaturated fatty acid supplementation for improving peripheral nerve health: protocol for a systematic review

Alexis Ceecee Zhang,¹ Richard J MacIsaac,^{2,3} Leslie Roberts,^{3,4} Jordan Kamel,^{3,4}
Jennifer P Craig,⁵ Lucy Busija,⁶ Laura E Downie¹

¹Department of Optometry and Vision Sciences, The University of Melbourne, Parkville, Victoria, Australia 3010; ²Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia 3065; ³Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia 3010; ⁴Centre for Clinical Neurosciences and Neurological Research, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia 3065; ⁵Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand 1023; ⁶Institute for Health and Ageing, Australian Catholic University, Fitzroy, Victoria, Australia 3065.

Word count: 4175 words

Corresponding author:

Dr Laura Downie

Department of Optometry and Vision Sciences

Level 4, Alice Hoy Building (Building 162)

The University of Melbourne, Parkville Victoria Australia 3010

Ph: +61 3 9035 3043, Fax: +61 3 9035 9905

Email: ldownie@unimelb.edu.au

ABSTRACT

Introduction: Damage to peripheral nerves occurs in a variety of health conditions. Preserving nerve integrity, to prevent progressive nerve damage, remains a clinical challenge. Omega-3 polyunsaturated fatty acids (PUFAs) are implicated in the development and maintenance of healthy nerves and may be beneficial for promoting peripheral nerve health. The aim of this systematic review is to assess the effects of oral omega-3 PUFA supplementation on peripheral nerve integrity, including both subjective and objective measures of peripheral nerve structure and/or function.

Methods and analysis: A systematic review of randomised controlled trials that have evaluated the effects of omega-3 PUFA supplementation on peripheral nerve assessments will be conducted. Comprehensive electronic database searches will be performed in OVID Medline, Embase, the Cochrane Central Register of controlled Trials (CENTRAL), US National Institutes of Health Clinical Trials Registry and the World Health Organisation International Clinical Trials Registry Platform (WHO ICTRP). The title, abstract and keywords of identified articles will be assessed for eligibility by two reviewers. Full text articles will be obtained for all studies judged as eligible or potentially eligible; these studies will be independently assessed by two reviewers to determine eligibility. Disagreements will be resolved by consensus. Risk of bias assessment will be performed using the Cochrane Collaboration risk of bias tool to appraise the quality of included studies. If clinically meaningful, and there are a sufficient number of eligible studies, a meta-analysis will be conducted and a summary of findings table will be provided.

Ethics and dissemination: This is a systematic review that will involve the analysis of previously published data and therefore ethics approval is not required. A

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

manuscript reporting the results of this systematic review will be published in a peer-reviewed journal and may also be presented at relevant scientific conferences.

For peer review only

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This will be the first systematic review to consider the efficacy and safety of omega-3 PUFA supplementation on peripheral nerve structure and function.
- This systematic review will only consider data from randomised controlled trials, which provide the highest level of evidence for single intervention studies.
- This review will be conducted according to the Cochrane Handbook for Systematic Reviews of Interventions, and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) statement.
- As we will include studies that have evaluated the use of omega-3 PUFA supplementation for treating any form of peripheral nerve damage, there may be limited scope to perform a meta-analysis due to clinical heterogeneity.
- There are currently no gold standard outcome measures for assessing peripheral neuropathy, which may affect the capacity to quantitatively synthesise data from individual studies to derive clear estimates of treatment effect(s).

BACKGROUND

Description of the condition

The peripheral nervous system encompasses the nerves mediating sensory, motor and autonomic functions that are located outside of the brain and spinal cord. Alterations to the anatomical integrity of the peripheral nerves can adversely affect their function, presenting clinically as abnormal or loss of sensation, weakness and/or as changes to autonomic function.[1] England describes peripheral neuropathy as “a general term that indicates any disorder of the peripheral nervous system;”[2] this is a broad definition that includes nerve damage due to a variety of aetiologies. The pathophysiological mechanisms underlying both the development and progression of peripheral neuropathy are complex and may depend on the cause. Some of these mechanisms include altered metabolism and intracellular signaling,[3] vascular and inflammatory stress,[4] and reactive oxygen species formation[5].

The most common systemic cause of peripheral neuropathy, which is evident in over 50% of individuals affected by the condition, is diabetes mellitus; the risk of peripheral neuropathy increases with longer disease duration,[6] and may be correlated with the degree of glycaemic control, particularly in type-1 diabetes. [7-10] Other causes include hereditary neuropathies (e.g., Charcot-Marie-Tooth Syndrome), post-infectious and inflammatory neuropathies (e.g., Guillain-Barré Syndrome) and drug-induced neuropathies (e.g., platinum analogues, thalidomide, alcohol).[11] Up to one-third of cases do not have an identified aetiology, and are thus defined as idiopathic peripheral neuropathies.[12]

1
2
3 Clinical evaluations of peripheral nerve integrity generally include a combination of
4 symptoms, signs and electrodiagnostic studies, which aim to evaluate the extent of
5 nerve damage.[2] Symptoms and signs of nerve damage are often assessed using
6 validated neuropathy scales or composite scores (which combine symptomatology
7 with clinical measures of nerve function). Nerve biopsies are invasive and, as a result,
8 not easily repeatable, and are therefore not frequently used as an outcome parameter
9 in longitudinal studies, but are rather reserved for diagnostic purposes.[13]
10
11
12
13
14
15
16
17
18
19

20 Electrodiagnostic testing examines the characteristics of the conduction of an
21 electrical signal that travels through a single nerve. These tests are useful in providing
22 diagnostic information and for longitudinally monitoring disease progression.[14]
23 Nerve conduction studies are reproducible and correlate well with underlying
24 structural abnormalities,[15] but the precision of these tests is limited to detecting
25 changes in large myelinated nerve fibres, as they are not sufficiently sensitive to
26 detect small nerve fibre damage.[16, 17] Quantitative sensory tests, which quantify
27 thermal and pain thresholds, can be used to evaluate small nerve fibre function.[17]
28 Skin biopsies offer an alternative method to accurately diagnose and classify the
29 extent of small fibre neuropathy, even in the absence of large fibre nerve damage.[17,
30 18] Cutaneous silent period (CSP) testing is a reproducible measurement of the
31 noniceptive spinal reflex where thinly myelinated A-delta fibres are the afferent arm.
32 Quantitative sudomotor axonal reflex testing (QSART) assesses the function of
33 unmyelinated post-ganglionic sudomotor C-fibres.[19, 20] These are amongst several
34 other methods to assess various small fibre types, and as each individual test may
35 have a relatively low sensitivity a combination of modalities is usually preferable to
36 better assess small fibre function.[21]
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 Recently, corneal confocal microscopy has been applied to visualise small nerve
6 fibres *in vivo*.^[22] This technique has been shown to correlate well with
7 intraepidermal nerve fibre biopsy results^[23] and is useful for detecting and
8 documenting various types of small fibre neuropathies.^[24-27] Corneal confocal
9 microscopy has also been suggested to be useful for monitoring disease progression,
10 and as a marker for improvements in nerve function, in the investigation of
11 therapeutic targets for diabetic peripheral neuropathy.^[28-30]
12
13
14
15
16
17
18
19
20
21

22 Peripheral neuropathies are typically treated based on their subtype and/or underlying
23 cause(s). Treatments primarily aim to manage the underlying condition to prevent
24 progressive nerve damage and to treat any associated symptoms.^[2, 16, 31] The
25 consequences associated with symptoms of neuropathic impairment do not only affect
26 an individual's quality of life, but remain an economic burden in the cost of
27 healthcare and medical resources.^[32-34] This is especially true in chronic conditions
28 such as diabetes, where lifetime care is required.^[3]
29
30
31
32
33
34
35
36
37
38
39

40 **Description of the intervention**

41
42 Omega-3 polyunsaturated fatty acids (PUFAs) are essential fatty acids (EFAs) with
43 multiple double bonds, the first of which is located at the third carbon from the
44 methyl end of the molecule. Short-chain omega-3 PUFAs, alpha-linolenic acid
45 (ALA), found in plant sources, is a metabolic precursor to the long-chain omega-3
46 PUFAs docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are
47 present in high abundance in oily fish. As humans do not have the enzymes to
48 synthesise these fatty acids *de novo*, omega-3 PUFAs must be obtained from the diet
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 or through supplementation.[35] The other major class of EFAs are the omega-6 fatty
4 acids, which derive from the diet in the form of linolenic acid (LA) and are elongated
5 *in vivo* to gamma-linoleic acid (GLC) and arachidonic acid (AA). Most eicosanoids
6 derived from the omega-6 dependent AA-pathway are pro-inflammatory; in contrast,
7 long-chain omega-3 fatty acids bias prostaglandin metabolism towards the production
8 of anti-inflammatory eicosanoids.
9
10
11
12
13
14

15
16
17
18 As omega-3 PUFAs competitively inhibit the metabolic conversion of omega-6
19 PUFAs,[36] the balance of omega-3 to omega-6 fatty acid consumption can affect
20 systemic inflammatory processes and immune activity. The ratio of consumed omega-
21 6 to omega-3 in typical Western diets is approximately 15 to 1, whereas a ratio of 4 to
22 1 is considered optimal.[37] Increased consumption of omega-3 PUFAs is considered
23 to provide a range of potential general health benefits, including a reduced risk of
24 cardiovascular disease[38, 39] and lowered systemic triglycerides[40]. DHA, as an
25 integral component in cellular membrane structures of the brain and retina, has been
26 implicated in perinatal visual and neural development.[41-43] In ocular conditions,
27 omega-3 fatty acids supplements can reduce the symptoms and clinical signs
28 associated with ocular surface inflammation in dry eye disease.[44] The American
29 Heart Foundation recommends a daily intake, for adults, of 500mg of long-chain
30 omega-3 PUFAs,[45] and up to 4g/day in hypertriglyceridemia.[46]
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **How the intervention might work**

50
51 Once consumed, omega-3 PUFAs alter membrane protein activity and cellular
52 signaling response, to reduce immune activity and the concentration of systemic lipid
53 inflammatory mediators.[47] The incorporation of omega-3 PUFAs into cellular
54
55
56
57
58
59
60

1
2
3 membranes, and their subsequent effect on membrane activity, has been shown to
4 alter vascular function, improve sciatic nerve blood flow and enhance nerve
5 conduction velocity in a rat model of experimental diabetic neuropathy.[48]
6
7
8
9

10
11 Omega-3 PUFAs also affect intracellular signalling pathways and the expression of
12 genes, some of which may be associated with the regulation of neuron growth and
13 neuroprotection.[49] In animal models of diabetes, omega-3 PUFA supplementation
14 has been shown to attenuate adverse changes in nerve structure and function.[50, 51]
15
16 Mice enriched with genes that increase endogenous profiles of omega-3 PUFAs have
17 been shown to have reduced neuronal cell death and increased recovery to mechanical
18 stress and peripheral nerve injury.[52] Omega-3 PUFAs have also been demonstrated
19 to promote neurite growth in rat sensory neurons.[53]
20
21
22
23
24
25
26
27
28
29
30

31 Derivatives of omega-3 PUFA metabolism, resolvins and protectins, which are
32 oxygenated metabolites from EPA and DHA respectively, may further promote
33 neuronal function. Neuroprotectin D-1 has been shown to facilitate the regeneration
34 of corneal nerves following refractive surgery and neurite growth from the trigeminal
35 ganglion of mice [54] and to prevent neuropathic pain after peripheral nerve
36 injury.[55]
37
38
39
40
41
42
43
44
45
46

47 **Why it is important to do this review**

48
49 This will be the first systematic review to consider the potential effects of omega-3
50 PUFA supplementation on peripheral nerve integrity. Omega-3 PUFA
51 supplementation has been shown to reduce neuronal damage and enhance recovery
52 following nerve injury in experimental animal models of peripheral neuropathy.
53
54
55
56
57
58
59
60

1
2
3 Confirmation of these effects in clinical populations would contribute significantly
4 towards enhancing the clinical management of peripheral neuropathy. A therapeutic
5 agent to prevent the pathogenesis of, or slow the progression of, peripheral nerve
6 damage has the potential to greatly improve clinical outcomes. Furthermore, the
7 potential for omega-3 PUFA supplements to alleviate neuropathy-associated
8 symptoms would be predicted to reduce impairment on an individual's quality of life
9 and lessen the economic burden of peripheral neuropathy in the community.
10
11
12
13
14
15
16
17
18
19

20 **OBJECTIVES**

21
22 The primary objective of this systematic review is to evaluate the efficacy and safety
23 of oral omega-3 PUFA supplements for improving peripheral nerve health. Efficacy
24 outcomes will consider both subjective endpoints (i.e., symptoms) and objective
25 clinical measures, including changes to peripheral nerve structure and function.
26
27
28
29
30
31
32

33 **METHODS AND ANALYSIS**

34
35 We will conduct the proposed systematic review and meta-analyses according to the
36 recommendations stated in the *Cochrane Handbook for Systematic Reviews of*
37 *Interventions*,^[56] and following the Preferred Reporting Items for Systematic
38 Reviews and Meta Analyses (PRISMA) statement.^[57] The protocol for this review
39 has been registered in the PROSPERO International prospective register of systematic
40 reviews, (ID 86297).
41
42
43
44
45
46
47
48
49
50
51
52

53 **Eligibility criteria**

54
55
56
57
58
59
60

1
2
3 All studies published from the date of database inception until 21st November 2017
4 will be included. Studies will be selected according to the following eligibility
5 criteria:
6
7
8
9

10 11 **Types of studies**

12 We will include randomised controlled trials (RCTs) where participants were
13 allocated to consume oral omega-3 PUFA supplements. We will exclude quasi-
14 randomised trials. We will not exclude studies based upon language, publication
15 status, year, or the number of participants. In cases where more than one publication
16 reporting data from the same cohort of participants exist (i.e., from the same trial), the
17 study reporting on the largest number of participants will be included. Published
18 conference abstracts will be eligible for inclusion.
19
20
21
22
23
24
25
26
27
28
29
30

31 **Types of participants**

32 We will include studies involving adults (i.e., aged 18 years or older), recruited from
33 within any study setting, where the structure and/or function of peripheral nerves was
34 assessed. To be eligible for inclusion in the review, studies need to include at least
35 one subjective measure of peripheral neuropathy (e.g., symptom score), one
36 composite measure of peripheral neuropathy (i.e., combining subjective and objective
37 measures), or one objective measure of peripheral nerve structure (e.g., nerve biopsy)
38 or function (e.g., nerve conduction studies).
39
40
41
42
43
44
45
46
47
48
49
50

51 **Types of interventions**

52 We will consider interventions where participants were randomised to oral
53 supplementation with short-chain and/or long-chain omega-3 PUFAs. We will accept
54
55
56
57
58
59
60

1
2
3 studies that administered omega-3 supplements in any form or dosage. We will
4
5 exclude studies where the intervention was administered in the form of dietary
6
7 manipulation (i.e., a food-based intervention), and where omega-3 PUFA supplements
8
9 were administered in combination with another intervention (including other
10
11 nutritional interventions), unless the intervention was administered in the same dose
12
13 and frequency in the comparator group. We will consider studies where omega-3
14
15 PUFA supplements were compared to placebo or no treatment.
16
17
18
19

20 **Types of outcome measures**

21
22 There are no gold standard or universally accepted outcome measures for peripheral
23
24 nerve assessment. In selecting the outcome measures for this review, we considered
25
26 the recommendations provided by the European Neuromuscular Centre (ENMC)
27
28 International workshop: Selection of Outcome Measures for Peripheral Neuropathy
29
30 Clinical Trials (10-12 December 2014), taking into account both subjective and
31
32 clinical measures.[58]
33
34
35
36
37

38 We will assess all outcome measures at six months of follow-up, with an acceptable
39
40 follow-up range of between three and nine months from baseline. If studies do not
41
42 report the change from baseline, we will utilise data reported at the end of the follow-
43
44 up period.
45
46
47
48

49 **Primary outcomes**

50
51 The primary outcome will be the change, from baseline, in peripheral neuropathy
52
53 impairments, as quantified by validated, composite (i.e., combining symptoms plus
54
55 objective measures) neuropathy measures. We have not been prescriptive in our
56
57
58
59
60

1
2
3 selection of particular scales as there are no universally agreed scoring systems;
4
5 examples of validated, composite neuropathy assessment scales include the Michigan
6
7 Diabetic Neuropathy Score (MDNS),[59] Neuropathy Impairment Score (NIS)[60]
8
9 and Total Neuropathy Score (TNS).[61] For the purpose of this review, we define a
10
11 ‘validated’ measure being a survey instrument that has been psychometrically tested.
12
13

14 15 16 **Secondary outcomes**

17
18 We will consider the following secondary outcomes:
19

- 20
21 1. Symptoms: change, from baseline, in symptoms of peripheral neuropathy,
22
23 measured by a validated, patient-assessed symptom score.
- 24
25 2. Pain: change, from baseline, in mean scores of pain, measured by a validated,
26
27 patient-assessed pain scale. Examples of validated scales include the visual
28
29 analogue scale (VAS),[62] Likert scales[63, 64] and the McGill Pain
30
31 Questionnaire (MPQ).[65]
- 32
33 3. Disability: change, from baseline, in the mean score of a patient-reported
34
35 disability measure. Examples of validated disability measures include the
36
37 Overall Neuropathy Limitation Scale[66] and the Overall Disability Sum Score
38
39 (ODSS).[67]
- 40
41 4. Anatomical markers:
42
43
 - 44
45 a. Change, from baseline in central corneal nerve fibre length (CNFL),
46
47 defined as the total length of nerves in a given area, measured in
48
49 mm/mm^2 , using a laser-scanning in vivo confocal microscope (IVCM);
 - 50
51 b. Change, from baseline in intraepidermal nerve fibre density (IENFD).
- 52
53 5. Nerve Conduction Studies (NCS): Change, from baseline, in nerve conduction
54
55 study parameters, as recommended by England (2005):[68]
56
57
58
59
60

- 1
- 2
- 3 a. Sensory nerve action potential (SNAP) amplitudes of the sural, median
- 4 and ulnar nerves;
- 5
- 6
- 7 b. SNAP latencies of the sural, median and ulnar nerves;
- 8
- 9
- 10 c. Sensory nerve conduction velocity (NCV) of the sural, median and
- 11 ulnar nerves;
- 12
- 13 d. Distal compound motor action potential (CMAP) amplitude of the
- 14 peroneal, tibial, median and ulnar nerves;
- 15
- 16 e. CMAP latency of the peroneal, tibial, median and ulnar nerves;
- 17
- 18
- 19
- 20 f. Motor NCV of the peroneal and ulnar Motor NCV of the peroneal,
- 21 tibial, medium and ulnar nerves;
- 22
- 23
- 24 g. Minimum F-wave latency of the peroneal, tibial, median and ulnar
- 25 nerves.
- 26
- 27
- 28
- 29 6. Sensory function in the cornea: change, from baseline, in corneal sensation, as
- 30 quantified using:
- 31
- 32
- 33 a. Contact aesthesiometry, to quantify mechanical detection thresholds
- 34 using the Cochet-Bonnet aesthesiometer (measured in millimetres);
- 35
- 36
- 37 b. Non-contact aesthesiometry, to quantify corneal sensation quantified
- 38 using an air-based aesthesiometer (measured in millibars).
- 39
- 40
- 41
- 42 7. Sensory function in the skin: Change, from baseline, in sensory function test
- 43 scores:
- 44
- 45
- 46 a. Mechanical detection thresholds, measured using pressure
- 47 aesthesiometry (e.g., von Frey hair aesthesiometer);
- 48
- 49
- 50 b. Cold detection thresholds measured using quantitative sensory testing
- 51 (QST) methods;
- 52
- 53
- 54 c. Warm detection thresholds measured using QST methods;
- 55
- 56
- 57
- 58
- 59
- 60

d. Thermal pain thresholds, for cold and hot stimuli, measured using QST methods.

8. Adverse events: we will consider all adverse events, and will analyse them in the following categories: (i) any adverse events, (ii) adverse events leading to discontinuation of the interventions, and (iii) serious adverse events, being those leading to hospitalization or prolonged admission, a life-threatening event or death.

Search methods for identification of studies

We will conduct comprehensive electronic database searches in: the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 10, October 2017), Ovid MEDLINE, Ovid MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily (January 1946 to November 2017), EMBASE (January 1947 to November 2017). We will also search the US National Institutes of Health Clinical Trials Registry (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/en/). We will not impose any restrictions on date or language in our search strategies. Search strategies for all electronic searches are included in Appendices 1 – 5. We will additionally search the bibliographies of included RCTs to identify any other potentially relevant studies.

Data collection and analysis

After the search strategies are performed within each electronic database, the reference lists will be imported into EndNote. Duplicate entries will be identified and

1
2
3 removed. The final reference library will be imported into Covidence,[69] the
4
5 standard production platform for Cochrane reviews, for the study selection process.
6
7
8

9 10 **Selection of studies**

11 The titles, keywords and abstracts of all unique articles, identified by the search
12 strategies, will be independently reviewed by two review authors to identify
13 potentially eligible studies. The full text papers of articles identified as relevant or
14 potentially relevant, by at least one reviewer, will be retrieved for full text screening.
15 Full text articles will be independently screened by two review authors and assessed
16 for eligibility according to the pre-specified inclusion and exclusion criteria. Reasons
17 for exclusion will be identified and recorded for ineligible studies that progress to the
18 full text screening stage. Any disagreements in eligibility assessment will be
19 adjudicated between the two reviewers; if consensus cannot be achieved, a third
20 independent author will be consulted to reach consensus. We will include a PRISMA
21 flow diagram (summarising the article selection process) and a ‘Characteristics of
22 excluded studies’ table (with reasons for study exclusion).
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Data extraction and management**

41 Two review authors will independently extract outcome data and key study
42 characteristics for all included studies. Any discrepancies will be resolved by
43 discussion and consensus. We will contact the study authors of relevant trials, by
44 email, if further information or clarification is required. If we fail to receive a
45 response from the corresponding author within four weeks, or if the authors are
46 unable to provide us with the requested information, we will use the information that
47 is available.
48
49
50
51
52
53
54
55
56
57
58
59
60

For each study, we will extract the following information:

1. Article details: year of publication, journal of publication, language, publication status;
2. Study details: dates study conducted, trial registration number, country, study setting, corresponding author details (name, institution, email, address) and whether the study investigators were contacted for further information;
3. Methods: exclusions after randomisation, losses to follow-up, how missing data were handled, whether a sample size calculation was reported;
4. Participants: number of participants in each intervention group, participant baseline characteristics (i.e., age, gender and/or sex (as specified by the study authors), underlying conditions, peripheral neuropathy diagnostic criteria), participant inclusion criteria and exclusion criteria, comparison of groups at baseline;
5. Interventions: intervention(s) and comparator (type (long- or short-chain), dose (milligrams/day), duration of treatment), concomitant medications or treatments, compliance measures (i.e., whether compliance was assessed, and the method used, e.g., returned capsule counts, red blood cell fatty acid profiles, etc.);
6. Outcomes: pre-specified primary and secondary outcome measures, time points of assessments;
7. Other: sources of funding statement (i.e., present or absent), actual source of funding (e.g., industry funding), conflicts of interest statement (i.e., present or absent), nature of conflict of interest (e.g., industry employee).

Assessment of risk of bias in included studies

Two review authors will independently assess the risk of bias for each included study using *the Cochrane Handbook for Systematic Reviews* guidelines. Assessment of bias will be considered using the following domains:

1. Selection bias (random sequence generation and allocation concealment);
2. Performance bias (blinding of participants and all study personnel);
3. Detection bias (blinding of outcome assessors);
4. Attrition bias (incomplete outcome data);
5. Reporting bias (selective reporting of outcomes);
6. Other sources of bias (funding source, conflicts of interest).

Each review author will judge the risk of bias in each domain as: (i) low risk, (ii) unclear risk or (iii) high risk. Disagreements in bias assessment will be resolved by consensus between the two reviewers.

Measures of treatment effect

We will analyse data according to the methods described in Chapter 9 of the *Cochrane Handbook for Systematic Reviews of Interventions*.^[56]

As all of the pre-defined outcomes are continuous measures, we will extract information on the change in mean from baseline, and standard deviations of change, for the intervention and comparison groups. If change from baseline is not reported, we will extract information on the mean and standard deviation of the outcome, for the intervention and comparator groups, at the specified follow-up period. The effects of the interventions will be expressed as the mean difference (MD), with 95%

1
2
3 confidence intervals (CIs), between the intervention and comparator groups for
4 significant outcomes ($p < 0.05$); exact p-values will be reported.
5
6
7

8 9 **Unit of analysis issues**

10
11 The unit of analysis for this review will be the individual participant. In studies where
12 outcomes were measured in ocular tissues, the unit of analysis will be the enrolled
13 study eye of the participant. In studies where participants were randomly allocated to
14 treatment, there will be no unit of analysis issues if only one eye per person is
15 included in the trial, or if both eyes per person are included and the average value of
16 both eyes are reported. In studies where participants were randomly allocated to
17 treatment and both eyes were included, but reported separately, we will analyse this as
18 clustered data (i.e. adjusted for within-person correlation). We may have to contact
19 the trial investigators for further information to do this.
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Dealing with missing data**

34
35 For any studies where missing outcome data (e.g., omitted standard deviations,
36 standard errors) are identified, we will attempt to contact the study authors. If we fail
37 to receive a response from the corresponding authors in four weeks, or if the authors
38 are unable to provide us with the requested information, we will use the information
39 that is available. We will use imputed data, if this has been derived by the trial
40 investigators using an appropriate method, but will not impute missing data ourselves.
41
42
43
44
45
46
47
48
49
50

51 **Assessment of heterogeneity**

52
53 We will assess clinical and methodological heterogeneity in the included studies by
54 examining differences in the intervention (e.g., type, dose, form), participant
55
56
57

1
2
3 characteristics at baseline (e.g., age, gender/sex, cause of neuropathy, eligibility
4 criteria, etc.), and risk of bias. We will quantify statistical heterogeneity using the I^2
5 statistic, as outlined in Chapter 9 of the *Cochrane Handbook for Systematic Reviews*
6 *of Interventions*;^[56] we will consider an I^2 statistic of 60% or more as consistent with
7 a moderate level of heterogeneity. In measuring heterogeneity, we will also consider
8 the: (i) magnitude and direction of the effects of individual studies, and (ii) strength of
9 evidence for heterogeneity (using a p-value < 0.10 from the Chi-squared test as the
10 criterion for significant heterogeneity).
11
12
13
14
15
16
17
18
19
20
21

22 **Assessment of reporting biases**

23
24 If at least ten studies are included in a meta-analysis, we will use a funnel plot to
25 assess for any potential publication bias. We will interpret any asymmetries in the
26 funnel plot in association with the trial characteristics, considering relevant factors
27 such as sample size.
28
29
30
31
32
33
34

35 **Data synthesis**

36
37 We will undertake meta-analyses, for the primary and/or secondary outcomes, when
38 this would be clinically meaningful (i.e., for studies where the treatment, participants
39 and the underlying clinical questions are similar). If fewer than three RCTs are to be
40 included in a meta-analysis, we will use a fixed-effect model, otherwise we will use a
41 random-effects model.
42
43
44
45
46
47
48
49
50
51

52 If there is inconsistency between individual study results, such that the pooled results
53 may not provide a fair representation of the trial findings (e.g., the effects are in
54 opposite directions, or $I^2 > 60\%$ or the Chi-squared test p-value is <0.10), we will not
55
56
57
58
59
60

1
2
3 pool the study data but will instead describe the pattern of the individual study results.
4
5 If there is statistical heterogeneity but all of the effect estimates are in the same
6
7 direction, such that a pooled estimate would seem to provide a good summary of the
8
9 individual trial results, we may pool the data.
10

11
12 If a meta-analysis is not deemed appropriate, we will provide a descriptive or
13
14 tabulated results summary.
15

16 17 18 19 **Subgroup analysis and investigation of heterogeneity**

20
21 If sufficient data are available, we will perform subgroup analyses by prognostic
22
23 factors (e.g., type of disease (including sub-type of diabetes), severity of peripheral
24
25 neuropathy at baseline, and age) and by potential intervention effect modifiers (e.g.,
26
27 dose, duration and type of omega-3 PUFA supplement), as these factors are
28
29 potentially important to any observed treatment effects.
30

31 32 33 34 **Sensitivity analysis**

35
36 Provided there are sufficient data available, we will perform a sensitivity analysis for
37
38 the primary outcome (i.e., change in peripheral neuropathy impairment score), to
39
40 assess the impact of excluding studies that: i) were appraised as having a high risk of
41
42 bias due to lack of allocation concealment or lack of blinding of participants and
43
44 study personnel, ii) had more than 20 percent of participants that were lost to follow-
45
46 up, iii) were unpublished, and iv) were funded by industry.
47
48
49
50

51 52 **Summary of findings table**

53
54
55
56
57
58
59
60

1
2
3 Provided that sufficient data are available, we will provide a “Summary of findings”
4 table for the primary outcome (change in peripheral neuropathy as measured using a
5 validated composite neuropathy assessment) and the following secondary outcomes
6 (as previously defined): (i) Symptoms, (ii) Pain, (iii) Corneal nerve fibre length
7 (CNFL), (iv) Intraepidermal nerve fibre density (IENFD), (v) SNAP amplitudes of the
8 sural nerve, and (vi) Motor NCV of the peroneal nerve. We will follow the
9 recommendations specified in Chapter 11 of the *Cochrane Handbook for Systematic*
10 *Reviews of Interventions*.^[56] The strength and quality of the evidence for each
11 outcome will be assessed using the Grading of Recommendations Assessment,
12 Development and Evaluation (GRADE) approach.^[70]
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **CONCLUSIONS**

28
29 The term “peripheral neuropathy” describes a heterogeneous group of disorders that
30 cause damage to the peripheral nervous system. Currently, management approaches
31 for peripheral neuropathy are aimed primarily at addressing the underlying cause
32 and/or managing symptoms. For many causes of peripheral neuropathy, including
33 diabetes, reversing or even limiting the progression of nerve damage remains a
34 challenge with currently available therapeutics.
35
36
37
38
39
40
41
42
43

44 Omega-3 PUFAs are reported to be associated with a range of general health benefits
45 that include reducing the risk of cardiovascular disease,^[38, 39] lowering systemic
46 triglycerides^[40] and improving clinical symptoms of dry eye disease.^[44] In animal
47 models of experimental peripheral nerve injury, increasing endogenous levels of
48 omega-3 PUFAs have been shown to improve sciatic blood flow and accelerate the
49 recovery of neuronal function.^[50, 52, 53]
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 The aim of this systematic review is to assess the safety and efficacy of oral omega-3
6 PUFA supplementation for improving peripheral nerve health. If it is demonstrated
7 that omega-3 supplements can improve measures of peripheral nerve function and/or
8 quality of life, it is anticipated that this therapy would make a valuable contribution to
9 the current clinical management of peripheral neuropathy.
10
11
12
13
14
15
16
17

18 **AUTHORS' CONTRIBUTIONS**

19
20 All authors (ACZ, LED, LB, JK, RJM, LR and JPC) made contributions to the
21 conception and/or design of the work; and drafted (ACZ & LED) or revised (LB, JK,
22 RJM, LR and JPC) the protocol; and approved the final version of the manuscript; and
23 agree to be accountable for all aspects of the submitted work.
24
25
26
27
28
29
30

31 **FUNDING STATEMENT**

32
33 This work was supported by 2018 Melbourne Neuroscience Institute (MNI)
34 Interdisciplinary Seed Funding (LED, RJM, LR, JK); the funder had no role in the
35 design of this protocol and will not have any role in the undertaking, data analyses, or
36 reporting of the systematic review.
37
38
39
40
41
42
43

44 **COMPETING INTERESTS STATEMENT**

45
46 All authors declare no conflicts of interest relevant to this review.
47
48
49
50

51 **ACKNOWLEDGEMENTS**

52
53 We acknowledge the advice of Iris Gordon, Cochrane Eyes and Vision Group, who
54 provided feedback on the search strategies for this review.
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Hughes RA. Peripheral neuropathy. *BMJ*. 2002;324(7335):466-9.
2. England JD, Asbury AK. Peripheral neuropathy. *Lancet*. 2004;363(9427):2151-61.
3. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. *Lancet Neurol*. 2012;11(6):521-34.
4. Cameron NE, Cotter MA. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. *Curr Drug Targets*. 2008;9(1):60-7.
5. Cashman CR, Hoke A. Mechanisms of distal axonal degeneration in peripheral neuropathies. *Neurosci Lett*. 2015;596:33-50.
6. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. *Neurology*. 1993;43(4):817-24.
7. Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. *Diabetes Care*. 2014;37(1):9-16.
8. Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care*. 2017;40(1):136-54.
9. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. *N England J Med*. 2008;358(24):2545-59.

10. Charles M, Ejksjaer N, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbaek A. Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: the ADDITION-Denmark study. *Diabetes Care*. 2011;34(10):2244-9.
11. Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. *J Neurol Neurosurg Psychiatry*. 1997;62(4):310-8.
12. Gordon Smith A, Robinson Singleton J. Idiopathic neuropathy, prediabetes and the metabolic syndrome. *J Neurol Sci*. 2006;242(1-2):9-14.
13. Sommer CL, Brandner S, Dyck PJ, Harati Y, LaCroix C, Lammens M, et al. Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies. *J Periph Nerv Syst*. 2010;15(3):164-75.
14. Mallik A, Weir AI. Nerve conduction studies: essentials and pitfalls in practice. *J Neurol Neurosurg Psychiatry*. 2005;76(suppl 2):ii23-ii31.
15. Dyck PJ, Karnes JL, Daube J, O'Brien P, Service FJ. Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. *Brain*. 1985;108 (Pt 4):861-80.
16. Azhary H, Farooq MU, Bhanushali M, Majid A, Kassab MY. Peripheral neuropathy: differential diagnosis and management. *Am Fam Physician*. 2010;81(7):887-92.
17. Lauria G, Lombardi R. Skin biopsy: a new tool for diagnosing peripheral neuropathy. *BMJ*. 2007;334(7604):1159-62.
18. Hoeijmakers JG, Faber CG, Lauria G, Merkies IS, Waxman SG. Small-fibre neuropathies--advances in diagnosis, pathophysiology and management. *Nat Rev Neurol*. 2012;8(7):369-79.
19. Floeter MK. Cutaneous silent periods. *Muscle & nerve*. 2003;28(4):391-401.

- 1
2
3 20. Sletten DM, Weigand SD, Low PA. Relationship of Q-sweat to quantitative
4 sudomotor axon reflex test (QSART) volumes. *Muscle Nerve*. 2010;41(2):240-6.
5
6
7 21. Kamel JT, Vogrin SJ, Knight-Sadler RJ, Willems NK, Seiderer L, Cook MJ,
8 et al. Combining cutaneous silent periods with quantitative sudomotor axon reflex
9 testing in the assessment of diabetic small fiber neuropathy. *Clin Neurophysiol*.
10 2015;126(5):1047-53.
11
12 22. De Silva MEH, Zhang AC, Karahalios A, Chinnery HR, Downie LE. Laser
13 scanning in vivo confocal microscopy (IVCM) for evaluating human corneal sub-
14 basal nerve plexus parameters: protocol for a systematic review. *BMJ Open*.
15 2017;7(11):e018646.
16
17 23. Quattrini C, Tavakoli M, Jeziorska M, Kallinikos P, Tesfaye S, Finnigan J, et
18 al. Surrogate markers of small fiber damage in human diabetic neuropathy. *Diabetes*.
19 2007;56(8):2148-54.
20
21 24. Ferdousi M, Azmi S, Petropoulos IN, Fadavi H, Ponirakis G, Marshall A, et
22 al. Corneal Confocal Microscopy Detects Small Fibre Neuropathy in Patients with
23 Upper Gastrointestinal Cancer and Nerve Regeneration in Chemotherapy Induced
24 Peripheral Neuropathy. *PloS One*. 2015;10(10):e0139394.
25
26 25. Asghar O, Petropoulos IN, Alam U, Jones W, Jeziorska M, Marshall A, et al.
27 Corneal confocal microscopy detects neuropathy in subjects with impaired glucose
28 tolerance. *Diabetes Care*. 2014;37(9):2643-6.
29
30 26. Tavakoli M, Marshall A, Thompson L, Kenny M, Waldek S, Efron N, et al.
31 Corneal confocal microscopy: a novel noninvasive means to diagnose neuropathy in
32 patients with Fabry disease. *Muscle Nerve*. 2009;40(6):976-84.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 27. Sturniolo GC, Lazzarini D, Bartolo O, Berton M, Leonardi A, Fregona IA, et
4 al. Small fiber peripheral neuropathy in Wilson disease: an in vivo documentation by
5 corneal confocal microscopy. *Invest Ophthalmol Vis Sci.* 2015;56(2):1390-5.
6
7
8
9 28. Tavakoli M, Mitu-Pretorian M, Petropoulos IN, Fadavi H, Asghar O, Alam U,
10 et al. Corneal confocal microscopy detects early nerve regeneration in diabetic
11 neuropathy after simultaneous pancreas and kidney transplantation. *Diabetes.*
12 2013;62(1):254-60.
13
14
15 29. Tavakoli M, Kallinikos P, Iqbal A, Herbert A, Fadavi H, Efron N, et al.
16 Corneal confocal microscopy detects improvement in corneal nerve morphology with
17 an improvement in risk factors for diabetic neuropathy. *Diabet Med.*
18 2011;28(10):1261-7.
19
20
21 30. Pritchard N, Edwards K, Dehghani C, Fadavi H, Jeziorska M, Marshall A, et
22 al. Longitudinal assessment of neuropathy in type 1 diabetes using novel ophthalmic
23 markers (LANDMark): study design and baseline characteristics. *Diabet Res Clin*
24 *Practice.* 2014;104(2):248-56.
25
26
27 31. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic Somatic
28 Neuropathies. *Diabetes Care.* 2004;27(6):1458-86.
29
30
31 32. Alleman CJ, Westerhout KY, Hensen M, Chambers C, Stoker M, Long S, et
32 al. Humanistic and economic burden of painful diabetic peripheral neuropathy in
33 Europe: A review of the literature. *Diabetes Res Clin Pract.* 2015;109(2):215-25.
34
35
36 33. Mehra M, Merchant S, Gupta S, Potluri RC. Diabetic peripheral neuropathy:
37 resource utilization and burden of illness. *J Med Econ.* 2014;17(9):637-45.
38
39
40 34. McCarberg BH, Billington R. Consequences of neuropathic pain: quality-of-
41 life issues and associated costs. *Am J Manag Care.* 2006;12(9 Suppl):S263-8.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 35. Nettleton JA. Omega-3 fatty acids: comparison of plant and seafood sources in
4 human nutrition. *J Am Diet Assoc.* 1991;91(3):331-7.
5
6
7 36. Calder PC, Grimble RF. Polyunsaturated fatty acids, inflammation and
8 immunity. *Eur J Clin Nutr.* 2002;56 Suppl 3:S14-9.
9
10
11 37. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential
12 fatty acids. *Biomed Pharmacother.* 2002;56(8):365-79.
13
14
15 38. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in
16 cardiovascular disease and other chronic diseases. *Exp Biol Med.* 2008;233(6):674-
17 88.
18
19
20 39. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y,
21 et al. Effects of eicosapentaenoic acid on major coronary events in
22 hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint
23 analysis. *Lancet.* 2007;369(9567):1090-8.
24
25
26 40. Chauhan S, Kodali H, Noor J, Ramteke K, Gawai V. Role of Omega-3 Fatty
27 Acids on Lipid Profile in Diabetic Dyslipidaemia: Single Blind, Randomised Clinical
28 Trial. *J Clin Diagn Res.* 2017;11(3):Oc13-oc6.
29
30
31 41. Hibbeln JR, Davis JM, Steer C, Emmett P, Rogers I, Williams C, et al.
32 Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in
33 childhood (ALSPAC study): an observational cohort study. *Lancet.*
34 2007;369(9561):578-85.
35
36
37 42. McNamara RK. DHA deficiency and prefrontal cortex neuropathology in
38 recurrent affective disorders. *J Nutr.* 2010;140(4):864-8.
39
40
41 43. Birch EE, Hoffman DR, Uauy R, Birch DG, Prestidge C. Visual acuity and the
42 essentiality of docosahexaenoic acid and arachidonic acid in the diet of term infants.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 44. Deinema LA, Vingrys AJ, Wong CY, Jackson DC, Chinnery HR, Downie LE.
4 A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of
5 Omega-3 Supplements for Treating Dry Eye Disease. *Ophthalmology*.
6 2017;124(1):43-52.
7
8
9
10
11 45. Kris-Etherton PM, Harris WS, Appel LJ. Fish Consumption, Fish Oil, Omega-
12 3 Fatty Acids, and Cardiovascular Disease. *Circulation*. 2002;106(21):2747-57.
13
14
15 46. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al.
16 Triglycerides and Cardiovascular Disease. A Scientific Statement From the American
17 Heart Association. 2011;123(20):2292-333.
18
19
20
21 47. Gibney MJ, Hunter B. The effects of short- and long-term supplementation
22 with fish oil on the incorporation of n-3 polyunsaturated fatty acids into cells of the
23 immune system in healthy volunteers. *Eur J Clin Nutr*. 1993;47(4):255-9.
24
25
26
27 48. Coste TC, Gerbi A, Vague P, Pieroni G, Raccach D. Neuroprotective effect of
28 docosahexaenoic acid-enriched phospholipids in experimental diabetic neuropathy.
29 *Diabetes*. 2003;52(10):2578-85.
30
31
32
33 49. Kitajka K, Sinclair AJ, Weisinger RS, Weisinger HS, Mathai M, Jayasooriya
34 AP, et al. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene
35 expression. *Proc Natl Acad Sci USA*. 2004;101(30):10931-6.
36
37
38
39 50. Gerbi A, Maixent JM, Ansaldi JL, Pierlovisi M, Coste T, Pelissier JF, et al.
40 Fish oil supplementation prevents diabetes-induced nerve conduction velocity and
41 neuroanatomical changes in rats. *J Nutr*. 1999;129(1):207-13.
42
43
44
45 51. Yee P, Weymouth AE, Fletcher EL, Vingrys AJ. A role for omega-3
46 polyunsaturated fatty acid supplements in diabetic neuropathy. *Invest Ophthalmol Vis*
47 *Sci*. 2010;51(3):1755-64.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 52. Gladman SJ, Huang W, Lim SN, Dyall SC, Boddy S, Kang JX, et al.
4
5 Improved outcome after peripheral nerve injury in mice with increased levels of
6
7 endogenous omega-3 polyunsaturated fatty acids. *J Neurosci*. 2012;32(2):563-71.
8
9
10 53. Robson LG, Dyall S, Sidloff D, Michael-Titus AT. Omega-3 polyunsaturated
11
12 fatty acids increase the neurite outgrowth of rat sensory neurones throughout
13
14 development and in aged animals. *Neurobiol Aging*. 2010;31(4):678-87.
15
16 54. Cortina MS, He J, Russ T, Bazan NG, Bazan HE. Neuroprotectin D1 restores
17
18 corneal nerve integrity and function after damage from experimental surgery. *Invest*
19
20 *Ophthalmol Vis Sci*. 2013;54(6):4109-16.
21
22 55. Xu ZZ, Liu XJ, Berta T, Park CK, Lu N, Serhan CN, et al.
23
24 Neuroprotectin/protectin D1 protects against neuropathic pain in mice after nerve
25
26 trauma. *Ann Neurol*. 2013;74(3):490-5.
27
28
29 56. Higgins J, Green S, (editors). *Cochrane Handbook for Systematic Reviews of*
30
31 *Interventions Version 5.1.0: The Cochrane Collaboration; 2011 (updated March*
32
33 *2011). Available from: <http://handbook.cochrane.org>.*
34
35 57. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
36
37 systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*.
38
39 2009;151(4):264-9.
40
41
42 58. Merkies IS, Lauria G. 131st ENMC international workshop: selection of
43
44 outcome measures for peripheral neuropathy clinical trials 10-12 December 2004,
45
46 Naarden, The Netherlands. *Neuromuscular disord*. 2006;16(2):149-56.
47
48
49 59. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A
50
51 Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the
52
53 Diagnosis and Staging of Diabetic Neuropathy. *Diabetes Care*. 1994;17(11):1281-9.
54
55
56
57
58
59
60

- 1
2
3 60. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC.
4 Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy
5 Study of Healthy Subjects. *Neurology*. 1995;45(6):1115-21.
6
7
8
9 61. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, et
10 al. Total neuropathy score: validation and reliability study. *Neurology*.
11 1999;53(8):1660-4.
12
13
14
15 62. Wewers ME, Lowe NK. A critical review of visual analogue scales in the
16 measurement of clinical phenomena. *Res Nurs Health*. 1990;13(4):227-36.
17
18
19
20 63. Hasson D, Arnetz B. Validation and Findings Comparing VAS vs. Likert
21 Scales for Psychosocial Measurements. *Int Electronic J Health Educ*. 2005; 8:178-92.
22
23
24 64. Farrar JT, Young JP, Jr., LaMoreaux L, Werth JL, Poole RM. Clinical
25 importance of changes in chronic pain intensity measured on an 11-point numerical
26 pain rating scale. *Pain*. 2001;94(2):149-58.
27
28
29
30 65. Melzack R. The McGill Pain Questionnaire: major properties and scoring
31 methods. *Pain*. 1975;1(3):277-99.
32
33
34
35 66. Graham RC, Hughes RAC. A modified peripheral neuropathy scale: the
36 Overall Neuropathy Limitations Scale. *J Neurol Neurosurg Psychiatry*.
37 2006;77(8):973-6.
38
39
40
41 67. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA.
42 Clinimetric evaluation of a new overall disability scale in immune mediated
43 polyneuropathies. *J Neurol Neurosurg Psychiatry*. 2002;72(5):596-601.
44
45
46
47 68. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, et
48 al. Distal symmetric polyneuropathy: a definition for clinical research: report of the
49 American Academy of Neurology, the American Association of Electrodiagnostic
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Medicine, and the American Academy of Physical Medicine and Rehabilitation.
4
5 Neurology. 2005;64(2):199-207.
6

7 69. Covidence systematic review software Melbourne, Australia.: Veritas Health
8
9 Innovation; [cited 2017 November]. Available from: www.covidence.org.
10

11 70. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R,
12
13 Singh JA, et al. A GRADE Working Group approach for rating the quality of
14
15 treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

APPENDIX 1

MEDLINE (OviD) search strategy

Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to November 2017

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. (randomised or randomized).ab,ti.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp Diabetic Neuropathies/
13. exp Diabetic Foot/
14. exp Peripheral Nervous System Diseases/
15. neuropath*.tw.
16. exp Neuralgia/

17. neuralgia.tw.
18. exp Charcot-Marie-Tooth Disease/
19. exp Facial Nerve Diseases/
20. exp Nerve Regeneration/
21. exp Nerve Degeneration/
22. nerve*.tw.
23. exp Hyperalgesia/
24. allodynia.tw.
25. exp Sensation/
26. sensation.tw.
27. exp Sensation Disorders/
28. an?esthesiomet*.tw.
29. esthesiomet*.tw.
30. aesthesiomet*.tw.
31. (guillain and barre).tw.
32. (polyradiculoneuritis or polyradiculoneuropath* or polyradiculopath*).tw.
33. (inflammatory adj3 (polyneuropath* or mononeuropath* or polyradiculoneuropath*)).tw.
34. (amyloid adj3 neuropath*).tw.
35. (motor and sensory and neuropath* and hereditary).mp.

- 1
2
3 36. (hereditary and sensory and autonomic and neuropath*).mp.
4
5
6 37. (heredit* adj6 neuropath*).mp.
7
8
9 38. or/12-37
10
11
12 39. (omega-3 or omega 3).tw.
13
14
15 40. (PUFA* or LCPUFA* or polyunsaturated or poly-unsaturated).tw.
16
17
18 41. eicosapentaenoic.tw.
19
20
21 42. EPA.tw.
22
23
24 43. docosahexaenoic.tw.
25
26
27 44. DHA.tw.
28
29
30 45. exp Alpha-Linolenic Acid/
31
32
33 46. alpha-linolenic.tw.
34
35
36 47. Fatty acids/
37
38
39 48. Fatty Acids, Unsaturated/
40
41
42 49. Fatty Acids, Essential/
43
44
45 50. exp Fatty Acids, Omega-3/
46
47
48 51. (Fatty adj3 acid*).tw.
49
50
51 52. or/39-51
52
53
54 53. 11 and 38 and 53
55
56
57
58
59
60

APPENDIX 2

EMBASE (OviD) search strategy*Embase Classic + Embase 1947 to November 2017*

1. exp Randomized Controlled Trial/
2. Exp controlled clinical trial
3. (randomised or randomized).ab,ti.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp neuropathy/
13. exp neuralgia/
14. exp nerve regeneration/
15. exp peripheral nervous system/
16. neuropath*.tw.
17. neuralgia.tw.
18. nerve*

- 1
- 2
- 3 19. an?esthesiomet*.tw.
- 4
- 5
- 6 20. esthesiomet*.tw.
- 7
- 8
- 9 21. aesthesiomet*.tw.
- 10
- 11
- 12 22. Sensation*.tw.
- 13
- 14
- 15 23. exp sensation*/
- 16
- 17
- 18 24. exp hyperalgesia/
- 19
- 20
- 21 25. exp allodynia/
- 22
- 23
- 24 26. hyperalgesia.tw.
- 25
- 26
- 27 27. allodynia.tw.
- 28
- 29
- 30 28. (guillain and barre).tw.
- 31
- 32
- 33 29. (polyradiculoneuritis or polyradiculoneuropath* or polyradiculopath*).tw.
- 34
- 35
- 36 30. (inflammatory adj3 (polyneuropath* or mononeuropath* or
- 37 polyradiculoneuropath*).tw.
- 38
- 39
- 40
- 41 31. (amyloid adj3 neuropath*).tw.
- 42
- 43
- 44 32. (motor and sensory and neuropath* and hereditary).mp.
- 45
- 46
- 47 33. (hereditary and sensory and autonomic and neuropath*).mp.
- 48
- 49
- 50 34. (heredit* adj6 neuropath*).mp.
- 51
- 52
- 53 35. or/12-34
- 54
- 55
- 56 36. exp unsaturated fatty acid/
- 57
- 58
- 59 37. exp fish oil/
- 60

- 1
- 2
- 3 38. (PUFA* or LCPUFA* or polyunsaturated or poly-unsaturated).tw.
- 4
- 5
- 6 39. (omega-3 or omega 3).tw.
- 7
- 8
- 9 40. eicosapentaenoic.tw.
- 10
- 11
- 12 41. docosahexaenoic.tw.
- 13
- 14
- 15 42. alpha-linolenic.tw.
- 16
- 17
- 18 43. (Fatty adj3 acid*).tw.
- 19
- 20
- 21 44. EPA.tw.
- 22
- 23
- 24 45. DHA.tw.
- 25
- 26
- 27 46. or/36-45
- 28
- 29
- 30 47. 11 and 35 and 46
- 31
- 32
- 33
- 34
- 35

APPENDIX 3

Cochrane Central Register of controlled Trials (CENTRAL) search strategy

1. MeSH descriptor: [Diabetic Neuropathies] explode all trees
2. MeSH descriptor: [Diabetic Foot] explode all trees
3. MeSH descriptor: [Peripheral Nervous System Diseases] explode all trees
4. MeSH descriptor: [Neuralgia] explode all trees
5. MeSH descriptor: [Charcot-Marie-Tooth Disease] explode all trees
6. MeSH descriptor: [Facial Nerve Diseases] explode all trees
7. MeSH descriptor: [Nerve Regeneration] explode all trees

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
8. MeSH descriptor: [Nerve Degeneration] explode all trees
 9. (neuropath* or Neuralgia* or nerve*):ti,ab,kw
 10. MeSH descriptor: [Hyperalgesia] explode all trees
 11. MeSH descriptor: [Sensation] explode all trees
 12. MeSH descriptor: [Sensation Disorders] explode all trees
 13. (sensation* or hyperalgesia or allodynia):ti,ab,kw
 14. (an?esthesiomet* OR esthesiomet* OR aesthesiomet*):ti,ab,kw
 15. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14
 16. (omega-3 or omega 3 or ω-3 or ω3 or "ω 3"):ti,ab,kw
 17. (PUFA* or LCPUFA* or polyunsaturated or poly-unsaturated):ti,ab,kw
 18. MeSH descriptor: [Eicosapentaenoic Acid] explode all trees
 19. (Eicosapentaenoic OR EPA):ti,ab,kw
 20. MeSH descriptor: [Docosahexaenoic Acids] explode all trees
 21. (Docosahexaenoic OR DHA):ti,ab,kw
 22. MeSH descriptor: [Alpha-Linolenic Acid] explode all trees
 23. (Alpha-Linolenic):ti,ab,kw
 24. MeSH descriptor: [Fatty acids] this term only
 25. MeSH descriptor: [Fatty Acids, Unsaturated] this term only
 26. MeSH descriptor: [Fatty Acids, Essential] this term only
 27. MeSH descriptor: [Fatty Acids, Omega-3] explode all trees

1
2
3 28. (Fatty near/3 acid*):ti,ab,kw
4

5
6 29. #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or
7
8 #28
9

10
11 30. #15 and #29
12
13
14
15
16

17 **APPENDIX 4**

18 **US National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov) search** 19 20 21 **strategy** 22 23

24
25 Condition = neuropathy or nerve or sensation
26

27
28 Intervention = omega-3 or “omega 3” or polyunsaturated OR PUFA or “docosahexaenoic” or
29
30 DHA OR “eicosapentaenoic” or EPA or “fish oil” or "fish-oil"
31
32

33 34 35 36 **APPENDIX 5**

37 **World Health Organisation International Clinical Trials Registry Platform (WHO** 38 39 40 **ICTRP) search strategy** 41 42

43
44
45 Condition = nerve disorders or nerve disease or neuropathy or nerve or sensation
46

47
48 Intervention = omega-3 or omega 3 or polyunsaturated or PUFA or docosahexaenoic or
49
50 eicosapentaenoic or fish oil
51
52
53
54
55
56
57
58
59
60

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported in manuscript (page number + section details)
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	Not applicable
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	10 (methods and analysis)
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1 (title page)
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	23 (contribution of authors)
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	Not applicable
Support:			
Sources	5a	Indicate sources of financial or other support for the review	23 (funding statement)
Sponsor	5b	Provide name for the review funder and/or sponsor	23 (funding statement)
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	23 (funding statement)
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	5 (background)
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	10 (objectives)
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	10 (eligibility criteria)
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	15 (search methods for identification of studies)

Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	15 (search methods for identification of studies), appendix
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	16 (data collection and analysis)
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	16 (selection of studies)
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	17 (data extraction and management)
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	17 (data extraction and management)
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	12 (types of outcome measures)
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	18 (assessment of risk of bias in included studies)
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	21 (data synthesis)
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	21 (data synthesis)
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	20/21 (subgroup analysis and investigation of heterogeneity, sensitivity analysis)
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	21 (data synthesis)
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	20 (assessment of reporting biases)
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	22 (summary of findings table)

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (note when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.